SG11201408238WA - Substituted tricyclic compounds as fgfr inhibitors - Google Patents

Substituted tricyclic compounds as fgfr inhibitors

Info

Publication number: SG11201408238WA
Authority: SG; Singapore
Prior art keywords: delaware; international; pennsylvania; hockessin; fgfr
Prior art date: 2012-06-13

Application number

SG11201408238WA

Other languages

English (en)

Inventor

Liangxing Wu

Colin Zhang

Chunhong He

Yaping Sun

Liang Lu

Ding-Quan Qian

Meizhong Xu

Jincong Zhuo

Wenqing Yao

Original Assignee

Incyte Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-13

Filing date

2013-06-12

Publication date

2015-01-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49486650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201408238W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-06-12 Application filed by Incyte Corp filed Critical Incyte Corp

2015-01-29 Publication of SG11201408238WA publication Critical patent/SG11201408238WA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pyridine Compounds (AREA)

SG11201408238WA 2012-06-13 2013-06-12 Substituted tricyclic compounds as fgfr inhibitors SG11201408238WA (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201261659245P	2012-06-13	2012-06-13
US201261691463P	2012-08-21	2012-08-21
US201261740012P	2012-12-20	2012-12-20
US201361774841P	2013-03-08	2013-03-08
PCT/US2013/045309 WO2014007951A2 (en)	2012-06-13	2013-06-12	Substituted tricyclic compounds as fgfr inhibitors

Publications (1)

Publication Number	Publication Date
SG11201408238WA true SG11201408238WA (en)	2015-01-29

Family

ID=49486650

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201408238WA SG11201408238WA (en)	2012-06-13	2013-06-12	Substituted tricyclic compounds as fgfr inhibitors
SG10201610416TA SG10201610416TA (en)	2012-06-13	2013-06-12	Substituted tricyclic compounds as fgfr inhibitors

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201610416TA SG10201610416TA (en)	2012-06-13	2013-06-12	Substituted tricyclic compounds as fgfr inhibitors

Country Status (38)

Country	Link
US (6)	US9611267B2 (es)
EP (5)	EP3822273B1 (es)
JP (8)	JP6301321B2 (es)
KR (3)	KR102406771B1 (es)
CN (3)	CN107652289B (es)
AR (1)	AR091424A1 (es)
AU (5)	AU2013287176C1 (es)
BR (1)	BR112014030812B1 (es)
CA (2)	CA2876689C (es)
CL (2)	CL2014003355A1 (es)
CO (1)	CO7240375A2 (es)
CY (4)	CY1118744T1 (es)
DK (3)	DK2861595T5 (es)
EA (1)	EA036592B1 (es)
EC (1)	ECSP22091792A (es)
ES (4)	ES2832497T3 (es)
HR (3)	HRP20170430T1 (es)
HU (4)	HUE042374T2 (es)
IL (5)	IL289834B2 (es)
LT (4)	LT3176170T (es)
LU (1)	LUC00222I2 (es)
ME (2)	ME03300B (es)
MX (3)	MX359293B (es)
MY (2)	MY171375A (es)
NL (1)	NL301131I2 (es)
NO (1)	NO2021034I1 (es)
NZ (3)	NZ702747A (es)
PE (2)	PE20190736A1 (es)
PH (2)	PH12019502809B1 (es)
PL (3)	PL3495367T3 (es)
PT (3)	PT3176170T (es)
RS (3)	RS58514B1 (es)
SG (2)	SG11201408238WA (es)
SI (3)	SI3176170T1 (es)
SM (3)	SMT201700146T1 (es)
TW (3)	TWI801156B (es)
UA (2)	UA125503C2 (es)
WO (1)	WO2014007951A2 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
DK2861595T5 (en)	2012-06-13	2018-01-15	Incyte Holdings Corp	Substituted tricyclic compounds as FGFR inhibitors
DK2861566T3 (en)	2012-06-13	2017-02-27	Hoffmann La Roche	NEW DIAZASPIROCYCLOALKANES AND AZASPIROCYCLOALKANES
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
CN104684915B (zh)	2012-09-25	2017-10-31	霍夫曼-拉罗奇有限公司	新型双环衍生物
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
AR094812A1 (es)	2013-02-20	2015-08-26	Eisai R&D Man Co Ltd	Derivado de piridina monocíclico como inhibidor del fgfr
AR095079A1 (es)	2013-03-12	2015-09-16	Hoffmann La Roche	Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
MY181497A (en)	2013-04-19	2020-12-23	Incyte Holdings Corp	Bicyclic heterocycles as fgfr inhibitors
CA2917667A1 (en)	2013-07-09	2015-01-15	Dana-Farber Cancer Institute, Inc.	Kinase inhibitors for the treatment of disease
CA2923523A1 (en)	2013-11-26	2015-06-04	F. Hoffmann-La Roche Ag	New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
EP3105218B1 (en) *	2014-02-13	2019-09-25	Incyte Corporation	Cyclopropylamines as lsd1 inhibitors
EP3590939A1 (en)	2014-03-26	2020-01-08	F. Hoffmann-La Roche AG	Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
EP3122751B1 (en)	2014-03-26	2019-10-30	F.Hoffmann-La Roche Ag	Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
WO2016024232A1 (en)	2014-08-11	2016-02-18	Acerta Pharma B.V.	Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
ES2921875T3 (es)	2014-08-11	2022-09-01	Acerta Pharma Bv	Combinaciones terapéuticas de un inhibidor BTK, un inhibidor PD-1 y/o un inhibidor PD-L1
HRP20211813T1 (hr)	2014-08-11	2022-03-04	Acerta Pharma B.V.	Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
MX369646B (es)	2014-08-18	2019-11-15	Eisai R&D Man Co Ltd	Sal de derivado de piridina monociclico y su cristal.
US9255096B1 (en)	2014-10-07	2016-02-09	Allergan, Inc.	Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors
US20160115164A1 (en) *	2014-10-22	2016-04-28	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
US9694084B2 (en)	2014-12-23	2017-07-04	Dana-Farber Cancer Institute, Inc.	Methods to induce targeted protein degradation through bifunctional molecules
MA41551A (fr) *	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2016219822B2 (en)	2015-02-20	2020-07-09	Incyte Holdings Corporation	Bicyclic heterocycles as FGFR inhibitors
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
RU2712222C2 (ru)	2015-03-25	2020-01-27	Нэшнл Кэнсер Сентер	Терапевтическое средство против рака желчных протоков
MA41898A (fr)	2015-04-10	2018-02-13	Hoffmann La Roche	Dérivés de quinazolinone bicyclique
KR20180043837A (ko)	2015-09-04	2018-04-30	에프. 호프만-라 로슈 아게	페녹시메틸 유도체
CA2983782A1 (en)	2015-09-24	2017-03-30	F. Hoffmann-La Roche Ag	Bicyclic compounds as atx inhibitors
WO2017050791A1 (en)	2015-09-24	2017-03-30	F. Hoffmann-La Roche Ag	New bicyclic compounds as dual atx/ca inhibitors
JP6845230B2 (ja)	2015-09-24	2021-03-17	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	デュアルａｔｘ／ｃａ阻害剤としての新規な二環式化合物
EP3353176B1 (en)	2015-09-24	2022-01-19	F. Hoffmann-La Roche AG	Bicyclic compounds as atx inhibitors
CN107459519A (zh)	2016-06-06	2017-12-12	上海艾力斯医药科技有限公司	稠合嘧啶哌啶环衍生物及其制备方法和应用
EP3596059B1 (en)	2017-03-16	2024-04-24	F. Hoffmann-La Roche AG	Heterocyclic compounds useful as dual atx/ca inhibitors
CN110382484B (zh)	2017-03-16	2022-12-06	豪夫迈·罗氏有限公司	新的作为atx抑制剂的二环化合物
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019098040A1 (ja)	2017-11-17	2019-05-23	Dic株式会社	重合性化合物、並びにそれを使用した液晶組成物及び液晶表示素子
CN111770909B (zh)	2018-03-01	2024-01-30	Dic株式会社	聚合性化合物以及使用其的液晶组合物和液晶显示元件
JPWO2019189241A1 (ja)	2018-03-28	2021-03-18	エーザイ・アール・アンド・ディー・マネジメント株式会社	肝細胞癌治療剤
CN110386932A (zh) *	2018-04-20	2019-10-29	艾科思莱德制药公司	用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
MA52493A (fr) *	2018-05-04	2021-03-10	Incyte Corp	Sels d'un inhibiteur de fgfr
JP2021523121A (ja) *	2018-05-04	2021-09-02	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	Ｆｇｆｒ阻害剤の固体形態及びその調製プロセス
CA3108065A1 (en)	2018-07-31	2020-02-06	Loxo Oncology, Inc.	Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
CN112867493A (zh)	2018-10-16	2021-05-28	达纳-法伯癌症研究所有限公司	野生型和突变型lrrk2的氮杂吲哚抑制剂
EP3898626A1 (en)	2018-12-19	2021-10-27	Array Biopharma, Inc.	Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN113474337A (zh)	2018-12-19	2021-10-01	奥瑞生物药品公司	作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
EP3942045A1 (en)	2019-03-21	2022-01-26	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN109939110A (zh) *	2019-05-08	2019-06-28	湖南中医药大学	药根碱在制备抗血栓药物中的应用
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
EP4011868B1 (en) *	2019-08-08	2025-01-01	Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.	Pyrazine-2(1h)-ketone compound preparation method
WO2021023192A1 (zh) *	2019-08-08	2021-02-11	漳州片仔癀药业股份有限公司	吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
US20220298120A1 (en) *	2019-08-15	2022-09-22	Black Diamond Therapeutics, Inc.	Alkynyl quinazoline compounds
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
AU2020366006A1 (en)	2019-10-14	2022-04-21	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
EP4054579A1 (en)	2019-11-08	2022-09-14	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN115151539A (zh)	2019-12-04	2022-10-04	因赛特公司	Fgfr抑制剂的衍生物
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
AU2021300429A1 (en)	2020-07-02	2023-02-16	Incyte Corporation	Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022193227A1 (en) *	2021-03-18	2022-09-22	Nutshell Biotech (Shanghai) Co., Ltd.	Fused ring compounds as inhibitors of fgfr tyrosine kinases
US12065494B2 (en)	2021-04-12	2024-08-20	Incyte Corporation	Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
WO2022261160A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
EP4436578A1 (en)	2021-11-22	2024-10-02	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a kras inhibitor
WO2023195018A1 (en) *	2022-04-05	2023-10-12	Msn Laboratories Private Limited, R&D Center	Solid dispersions of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one
WO2024206858A1 (en)	2023-03-30	2024-10-03	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en)	2023-05-04	2024-11-07	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
US11884667B1 (en)	2023-07-13	2024-01-30	King Faisal University	Substituted pyrrolo[2,3-c][2,7]naphthyridines as CK2 inhibitors
US20250049810A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
US11897883B1 (en)	2023-09-01	2024-02-13	King Faisal University	Pyrrolo[3,2-c][1,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11891377B1 (en)	2023-09-06	2024-02-06	King Faisal University	Pyrrolo[3,2-c][2,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11866437B1 (en)	2023-09-15	2024-01-09	King Faisal University	1,2-dioxo-2,3-dihydro-1H-pyrrolo[2,3-c]quinoline-7-carboxylic acid compounds as CK2 inhibitors
US20250154171A1 (en)	2023-10-12	2025-05-15	Revolution Medicines, Inc.	Ras inhibitors

Family Cites Families (813)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE280853C (es)
US850370A (en)	1906-06-05	1907-04-16	William L Hynes	Water-automobile.
DE2156720A1 (de)	1971-11-16	1973-05-24	Bayer Ag	Pyrimido eckige klammer auf 4,5-d eckige klammer zu pyrimidine
US3984021A (en)	1972-09-11	1976-10-05	Uhlig Gerhardt E	Safety closure container
US3894021A (en)	1974-01-28	1975-07-08	Squibb & Sons Inc	Derivatives of 1,7-dihydro-2H-pyrazolo{8 4{40 ,3{40 :5,6{9 pyrido{8 4,3-D{9 pyrimidine-2,4-(3H)-diones
JPS5120580B2 (es)	1974-06-19	1976-06-25
US4347348A (en)	1978-06-05	1982-08-31	Chernikhov Alexei Y	Heat-resistant heterocyclic polymers and methods for producing same
FR2428654A1 (fr)	1978-06-13	1980-01-11	Chernikhov Alexei	Polymeres heterocycliques thermostables et leurs procedes de preparation
CH635828A5 (de)	1978-08-30	1983-04-29	Ciba Geigy Ag	N-substituierte imide und bisimide.
CH641470A5 (de)	1978-08-30	1984-02-29	Ciba Geigy Ag	Imidgruppen enthaltende silane.
US4339267A (en)	1980-01-18	1982-07-13	E. I. Du Pont De Nemours And Company	Herbicidal sulfonamides
US4405786A (en)	1980-10-22	1983-09-20	Plastics Engineering Company	Addition products of di-acetylene-terminated polyimide derivatives and an dienophile having ethylene groups
US4405520A (en)	1980-10-22	1983-09-20	Plastics Engineering Company	Addition products of di-acetylene-terminated polymide derivatives and dienophiles having terminal maleimide grops
US4402878A (en)	1980-10-22	1983-09-06	Plastics Engineering Company	Addition products of di-acetylene-terminated polyimide derivatives with a polyimide having terminal non-conjugated acetylene groups
US4405519A (en)	1980-10-22	1983-09-20	Plastics Engineering Company	Di-Acetylene-terminated polyimide derivatives
US4460773A (en)	1982-02-05	1984-07-17	Lion Corporation	1-Phenyl-1H-pyrazolo [3,4-b]pyrazine derivatives and process for preparing same
DE3432983A1 (de)	1983-09-07	1985-04-18	Lion Corp., Tokio/Tokyo	1,5-disubstituierte 1h-pyrazolo(3,4-b)-pyrazin-derivate und antitumormittel, die diese enthalten
JPS62273979A (ja)	1986-05-21	1987-11-28	Lion Corp	１，５−置換−１Ｈ−ピラゾロ〔３，４−ｂ〕ピラジン誘導体及び該化合物を含有する抗腫瘍剤
JPS6310630A (ja)	1986-06-23	1988-01-18	Teijin Ltd	芳香族ポリアミドイミドエ−テルの製造法
JPS6317882A (ja)	1986-07-09	1988-01-25	Lion Corp	５−置換−１Ｈ−ピラゾロ〔３，４−ｂ〕ピラジン誘導体及び該化合物を含有する抗腫瘍剤
US4859672A (en)	1986-10-29	1989-08-22	Rorer Pharmaceutical Corporation	Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone
US4874803A (en)	1987-09-21	1989-10-17	Pennwalt Corporation	Dianhydride coupled polymer stabilizers
DE3814549A1 (de)	1987-10-30	1989-05-18	Bayer Ag	N-substituierte derivate von 1-desoxynojirimycin und 1-desoxymannonojirimycin, verfahren zu deren herstellung und deren verwendung in arzneimitteln
JPH029895A (ja)	1988-06-28	1990-01-12	Lion Corp	ヌクレオシド類似化合物及び抗腫瘍剤
DD280853A1 (de)	1989-03-21	1990-07-18	Akad Nauk Sssr	Bindemittel fuer elektroden, vorzugsweise fuer polymerelektroden
US5159054A (en)	1989-05-16	1992-10-27	The United States Of America As Represented By The Secretary Of The Navy	Synthesis of phthalonitrile resins containing ether and imide linkages
JP2845957B2 (ja)	1989-07-17	1999-01-13	三井化学株式会社	イミド環を有する新規ジフェノール類およびその製造方法
US5726302A (en)	1989-09-15	1998-03-10	Gensia Inc.	Water soluble adenosine kinase inhibitors
DE3937633A1 (de)	1989-11-11	1991-05-16	Bayer Ag	Heterocyclische verbindungen und deren verwendung als pigmente und farbstoffe
US5329046A (en)	1989-12-28	1994-07-12	Hoechst Aktiengesellschaft	Biscationic acid amide and imide derivatives and processes for their preparation
EP0506867B1 (de)	1989-12-28	1995-09-20	Hoechst Aktiengesellschaft	Biskationische säureamid- und -imidderivate als ladungssteuermittel
JP2883670B2 (ja)	1990-03-23	1999-04-19	三井化学株式会社	イミド環を有する新規ビスフェノール類およびその製造方法
GB9113137D0 (en)	1990-07-13	1991-08-07	Ici Plc	Thioxo heterocycles
CA2093322C (en)	1990-10-03	2002-01-29	Jonathan H. Hodgkin	Epoxy resins based on diaminobisimide compounds
JPH04158084A (ja)	1990-10-22	1992-06-01	Fuji Photo Film Co Ltd	記録材料
JPH04179576A (ja)	1990-11-14	1992-06-26	Fuji Photo Film Co Ltd	記録材料
JPH04328121A (ja)	1991-04-26	1992-11-17	Sumitomo Bakelite Co Ltd	半導体封止用エポキシ樹脂組成物
CA2110942A1 (en)	1991-06-14	1992-12-23	Pharmacia & Upjohn Company Llc	Imidazo¬1,5-a\|quinoxalines
DE4119767A1 (de)	1991-06-15	1992-12-17	Dresden Arzneimittel	Verfahren zur herstellung von (pyrimid-2-yl-thio- bzw. seleno)-essigsaeurederivaten
US5521184A (en)	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
JP3279635B2 (ja)	1992-05-18	2002-04-30	鐘淵化学工業株式会社	ヒドロシリル基含有イミド化合物
JP3232123B2 (ja)	1992-05-20	2001-11-26	鐘淵化学工業株式会社	硬化性組成物
NZ252064A (en)	1992-05-28	1995-09-26	Commw Scient Ind Res Org	Bismaleimide compounds; preparation thereof, curable compositions and impregnated fibre reinforced material containing them
JPH08504196A (ja)	1992-12-07	1996-05-07	コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション	ビスナドイミド
WO1994015995A1 (en)	1993-01-11	1994-07-21	The Trustees Of The University Of Pennsylvania	Polycyclic aromatic compounds having nonlinear optical properties
AU4293193A (en)	1993-04-28	1994-11-21	Du Pont Merck Pharmaceutical Company, The	Novel trisubstituted aromatic amines useful for the treatment of cognitive deficits
US5536725A (en)	1993-08-25	1996-07-16	Fmc Corporation	Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines
KR100263817B1 (ko)	1993-11-30	2000-08-16	윌리암스 로저 에이	염증치료용 치환 피라졸일벤젠술폰아미드
US5480887A (en)	1994-02-02	1996-01-02	Eli Lilly And Company	Protease inhibitors
BR9408531A (pt)	1994-02-02	1997-08-05	Lilly Co Eli	Inibidores da protease hiv e intermediários
PT790997E (pt)	1994-11-14	2000-06-30	Warner Lambert Co	6-aril pirido¬2,3-d\|pirimidinas e naftiridinas para inibir a proliferacao celular mediada pela quinase da tirosina proteica
US7125880B1 (en)	1995-06-06	2006-10-24	Pfizer Inc.	Corticotropin releasing factor antagonists
US5783577A (en)	1995-09-15	1998-07-21	Trega Biosciences, Inc.	Synthesis of quinazolinone libraries and derivatives thereof
JPH09188812A (ja)	1996-01-11	1997-07-22	Mitsui Toatsu Chem Inc	結晶化促進剤
JP3531169B2 (ja)	1996-06-11	2004-05-24	三菱ウェルファーマ株式会社	縮合ヘテロ環化合物およびその医薬用途
BR9710808A (pt)	1996-08-06	1999-08-17	Pfizer	Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos
US6184235B1 (en)	1996-08-14	2001-02-06	Warner-Lambert Company	2-phenyl benzimidazole derivatives as MCP-1 antagonists
JP3669783B2 (ja)	1996-08-21	2005-07-13	三井化学株式会社	有機電界発光素子
US5994364A (en)	1996-09-13	1999-11-30	Schering Corporation	Tricyclic antitumor farnesyl protein transferase inhibitors
WO1998018781A2 (en)	1996-10-28	1998-05-07	Versicor, Inc.	Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
EP0946523A1 (en)	1996-12-23	1999-10-06	Celltech Therapeutics Limited	Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
BR9807305A (pt)	1997-02-05	2000-05-02	Warner Lambert Co	Pirido [2,3-d] pirimidinas e 4-aminopirimidinas como inibidores de proliferação celular.
WO1998046609A1 (en)	1997-04-11	1998-10-22	Abbott Laboratories	Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission
BR9809515A (pt)	1997-05-28	2000-06-20	Rhone Poulenc Rorer Pharma	Composto, composição farmacêutica, e, processos para inibir a atividade da tirosina cinase pdgf, para inibir a atividade da tirosina cinase lck, para inibir a proliferação, diferenciação ou liberação de mediador celular em um paciente, para tratar um paciente sujeito a uma patologia ligada a um distúrbio hiperproliferativo, e para tratar a inflamação em um paciente que sofre da mesma
GB9716231D0 (en)	1997-07-31	1997-10-08	Amersham Int Ltd	Base analogues
CA2300478A1 (en)	1997-08-11	1999-02-18	Cor Therapeutics, Inc.	Selective factor xa inhibitors
JP4965021B2 (ja)	1997-08-20	2012-07-04	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	プロテインチロシンキナーゼおよび細胞周期キナーゼ仲介細胞増殖を阻害するためのナフチリジノン
US6465484B1 (en)	1997-09-26	2002-10-15	Merck & Co., Inc.	Angiogenesis inhibitors
JPH11171865A (ja)	1997-12-04	1999-06-29	Yoshitomi Pharmaceut Ind Ltd	縮合ヘテロ環化合物
US6350749B1 (en)	1998-02-20	2002-02-26	Takeda Chemical Industries, Ltd.	Aminoguanidine hydrazone derivatives, process for producing the same and drugs thereof
WO1999059975A1 (en)	1998-05-15	1999-11-25	Guilford Pharmaceuticals Inc.	Fused tricyclic compounds which inhibit parp activity
US20040044012A1 (en)	1998-05-26	2004-03-04	Dobrusin Ellen Myra	Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
ID27589A (id)	1998-05-26	2001-04-12	Warner Lambert Comapny	Pirimidina bisiklik dan dihidropirimidina bisiklik 3,4 sebagai penghambat proliferasi selular
AU4429799A (en)	1998-06-12	1999-12-30	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
BR9912938B1 (pt)	1998-08-11	2011-06-28		derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
JP2000123973A (ja)	1998-10-09	2000-04-28	Canon Inc	有機発光素子
ES2228123T3 (es)	1998-10-23	2005-04-01	F. Hoffmann-La Roche Ag	Heterociclos de nitrogeno biciclicos.
GB9823103D0 (en)	1998-10-23	1998-12-16	Pfizer Ltd	Pharmaceutically active compounds
US6133031A (en)	1999-08-19	2000-10-17	Isis Pharmaceuticals Inc.	Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en)	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
DE19912638A1 (de)	1999-03-20	2000-09-21	Bayer Ag	Naphthylcarbonsäureamid-substituierte Sulfonamide
DE19920790A1 (de)	1999-05-06	2000-11-09	Bayer Ag	Bis-Sulfonamide mit anti-HCMV-Wirkung
PE20010306A1 (es)	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP4041624B2 (ja)	1999-07-21	2008-01-30	三井化学株式会社	有機電界発光素子
IL148801A0 (en)	1999-09-24	2002-09-12	Janssen Pharmaceutica Nv	Antiviral compositions
DE19946289A1 (de)	1999-09-28	2001-03-29	Basf Ag	Benzodiazepin-Derivate, deren Herstellung und Anwendung
CA2388140C (en)	1999-10-21	2008-09-02	F. Hoffmann-La Roche Ag	Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
DE60033307T2 (de)	1999-10-21	2007-07-12	F. Hoffmann-La Roche Ag	Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen als p38-proteinkinase-inhibitoren
TWI271406B (en)	1999-12-13	2007-01-21	Eisai Co Ltd	Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
ATE353320T1 (de)	1999-12-29	2007-02-15	Wyeth Corp	Tricyclische proteinkinasehemmer
GEP20053429B (en)	2000-01-24	2005-01-25	Warner Lambert Co	3-Aminoquinazolin-2,4-Dione, Pharmaceutical Composition Containing Them and Use Thereof as Antibacterial Agents
BR0017075A (pt)	2000-01-27	2002-11-05	Warner Lambert Co	Derivados de piridopirimidinona para tratamento de doença neurodegenerativa
ES2290115T3 (es)	2000-02-01	2008-02-16	ABBOTT GMBH & CO. KG	Compuestos heterociclicos y su aplicacion como inhibidores de parp.
JP4574100B2 (ja)	2000-02-04	2010-11-04	ポートラファーマシューティカルズ，インコーポレイテッド	血小板ａｄｐレセプターインヒビター
ATE295365T1 (de)	2000-02-09	2005-05-15	Novartis Pharma Gmbh	Pyridinderivative als angiogenese- und/oder vegf- rezeptor-tyrosinkinase-inhibitoren
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
AU2001235804A1 (en)	2000-03-06	2001-09-17	Astrazeneca Ab	Therapy
JP2001265031A (ja)	2000-03-15	2001-09-28	Fuji Xerox Co Ltd	電子写真感光体、プロセスカートリッジ、及び、電子写真装置
DE10012549A1 (de)	2000-03-15	2001-09-20	Bayer Ag	Arzneimittel gegen virale Erkrankungen
TW200505900A (en)	2000-04-28	2005-02-16	Acadia Pharm Inc	Muscarinic agonists
JP2003532728A (ja)	2000-05-05	2003-11-05	コーセラピューティックス，インコーポレイテッド	ヘテロ二環式スルホンアミドおよび血小板ａｄｐレセプターインヒビターとしてのそれらの使用
AU2001268712A1 (en)	2000-06-23	2002-01-08	Bristol-Myers Squibb Company	1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor Xa inhibitors
MXPA03000051A (es)	2000-06-28	2003-08-19	Smithkline Beecham Plc	Procedimiento de molido en humedo.
US20050009876A1 (en)	2000-07-31	2005-01-13	Bhagwat Shripad S.	Indazole compounds, compositions thereof and methods of treatment therewith
CA2420967A1 (en)	2000-08-07	2002-02-14	Neurogen Corporation	Heterocyclic compounds as ligands of the gabaa receptor
HU230538B1 (hu)	2000-08-14	2016-11-28	Ortho Mcneil Pharmaceutical, Inc.	Szubsztituált pirazolok és ezeket tartalmazó gyógyszerkészítmények
KR100818056B1 (ko)	2000-09-06	2008-03-31	오르토-맥네일 파마슈티칼, 인코퍼레이티드	치환된 피라졸을 포함하는 알레르기 치료용 약제
GB0025782D0 (en)	2000-10-20	2000-12-06	Pfizer Ltd	Use of inhibitors
EP1217000A1 (en)	2000-12-23	2002-06-26	Aventis Pharma Deutschland GmbH	Inhibitors of factor Xa and factor VIIa
GB0100621D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds VI
GB0103926D0 (en)	2001-02-17	2001-04-04	Astrazeneca Ab	Chemical compounds
WO2002076953A1 (en)	2001-03-21	2002-10-03	Warner-Lambert Company Llc	New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6998408B2 (en)	2001-03-23	2006-02-14	Bristol-Myers Squibb Pharma Company	6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
JP2002296731A (ja)	2001-03-30	2002-10-09	Fuji Photo Film Co Ltd	熱現像カラー画像記録材料
AU2002255263B2 (en)	2001-04-16	2006-12-14	Eisai R&D Management Co., Ltd.	Novel 1H-indazole compound
US7074801B1 (en)	2001-04-26	2006-07-11	Eisai Co., Ltd.	Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
CZ20032946A3 (en)	2001-04-30	2004-05-12	Glaxoágroupálimited	Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
WO2002094825A1 (fr)	2001-05-22	2002-11-28	Banyu Pharmaceutical Co., Ltd.	Nouveau derive de spiropiperidine
US20030114448A1 (en)	2001-05-31	2003-06-19	Millennium Pharmaceuticals, Inc.	Inhibitors of factor Xa
MXPA03009894A (es)	2001-06-19	2004-02-17	Warner Lambert Co	Agentes antibacterianos.
US20030114467A1 (en)	2001-06-21	2003-06-19	Shakespeare William C.	Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
WO2003000690A1 (en)	2001-06-25	2003-01-03	Aventis Pharmaceuticals Inc.	Synthesis of heterocyclic compounds employing microwave technology
US20040235867A1 (en)	2001-07-24	2004-11-25	Bilodeau Mark T.	Tyrosine kinase inhibitors
BR0211740A (pt)	2001-08-07	2004-09-28	Banyu Pharma Co Ltd	Compostos espiro
IL160915A0 (en)	2001-09-19	2004-08-31	Aventis Pharma Sa	Indolizines inhibiting kinase proteins
KR100926194B1 (ko)	2001-10-30	2009-11-09	노파르티스 아게	Ｆｌｔ３ 수용체 티로신 키나아제 활성의 억제제로서의스타우로스포린 유도체
MXPA04004178A (es)	2001-11-01	2004-09-06	Janssen Pharmaceutica Nv	Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta.
KR20050042062A (ko)	2001-11-07	2005-05-04	에프. 호프만-라 로슈 아게	아미노피리미딘 및 피리딘
CA2466279A1 (en)	2001-11-13	2003-05-22	Dana-Farber Cancer Institute, Inc.	Agents that modulate immune cell activation and methods of use thereof
GB0129476D0 (en)	2001-12-10	2002-01-30	Syngenta Participations Ag	Organic compounds
PL220952B1 (pl)	2002-01-22	2016-01-29	Warner Lambert Co	2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
JP4201716B2 (ja)	2002-03-05	2008-12-24	メルクフロストカナダリミテツド	カテプシンシステインプロテアーゼ阻害剤
US6815519B2 (en)	2002-03-22	2004-11-09	Chung-Shan Institute Of Science & Technology	Acidic fluorine-containing poly (siloxane amideimide) silica hybrids
BR0308937A (pt)	2002-04-03	2005-01-04	Hoffmann La Roche	Compostos imidazo fundidos
MY138268A (en)	2002-05-15	2009-05-29	Janssen Pharmaceutica Nv	N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
JP4499342B2 (ja)	2002-05-16	2010-07-07	株式会社カネカ	ＳｉＨ基を含有する含窒素有機系化合物の製造方法
ATE478867T1 (de)	2002-05-23	2010-09-15	Novartis Vaccines & Diagnostic	Substituierte quinazolinone verbindungen
TW200406374A (en)	2002-05-29	2004-05-01	Novartis Ag	Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
US7119111B2 (en)	2002-05-29	2006-10-10	Amgen, Inc.	2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
PA8577501A1 (es)	2002-07-25	2004-02-07	Warner Lambert Co	Inhibidores de quinasas
RS51752B (en)	2002-07-29	2011-12-31	Rigel Pharmaceuticals	METHODS OF TREATMENT AND PREVENTION OF AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINDIAMINE COMPOUNDS
JP4252534B2 (ja)	2002-08-06	2009-04-08	エフ．ホフマン−ラロシュアーゲー	ｐ−３８ＭＡＰキナーゼインヒビターとしての６−アルコキシ−ピリド−ピリミジン類
EP1388541A1 (en)	2002-08-09	2004-02-11	Centre National De La Recherche Scientifique (Cnrs)	Pyrrolopyrazines as kinase inhibitors
US7084270B2 (en)	2002-08-14	2006-08-01	Hoffman-La Roche Inc.	Pyrimido compounds having antiproliferative activity
GB0220187D0 (en)	2002-08-30	2002-10-09	Novartis Ag	Organic compounds
GB0223349D0 (en)	2002-10-08	2002-11-13	Merck Sharp & Dohme	Therapeutic agents
US7112676B2 (en)	2002-11-04	2006-09-26	Hoffmann-La Roche Inc.	Pyrimido compounds having antiproliferative activity
TW200413381A (en)	2002-11-04	2004-08-01	Hoffmann La Roche	Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
WO2004043367A2 (en)	2002-11-06	2004-05-27	Bristol-Myers Squibb Company	Fused heterocyclic compounds and use thereof
AR042052A1 (es)	2002-11-15	2005-06-08	Vertex Pharma	Diaminotriazoles utiles como inhibidores de proteinquinasas
BR0316375A (pt)	2002-11-18	2005-10-04	Hoffmann La Roche	Diazinopirimidinas
US7504410B2 (en)	2002-11-28	2009-03-17	Schering Aktiengesellschaft	Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
EP1567497B1 (en)	2002-12-06	2009-09-23	Purdue Research Foundation	Pyridines for treating injured mammalian nerve tissue
WO2004052862A1 (ja)	2002-12-10	2004-06-24	Ono Pharmaceutical Co., Ltd.	含窒素複素環化合物およびその医薬用途
UA80171C2 (en)	2002-12-19	2007-08-27	Pfizer Prod Inc	Pyrrolopyrimidine derivatives
US7098332B2 (en)	2002-12-20	2006-08-29	Hoffmann-La Roche Inc.	5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
UA80767C2 (en)	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
JP4511943B2 (ja)	2002-12-23	2010-07-28	ワイスエルエルシー	Ｐｄ−１に対する抗体およびその使用
JP2004203749A (ja)	2002-12-24	2004-07-22	Kanegafuchi Chem Ind Co Ltd	ＳｉＨ基を含有する含窒素有機系化合物の製造方法
BRPI0406809A (pt)	2003-01-17	2005-12-27	Warner Lambert Co	Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
US7135469B2 (en)	2003-03-18	2006-11-14	Bristol Myers Squibb, Co.	Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
US7550590B2 (en)	2003-03-25	2009-06-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
GB0308208D0 (en)	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
KR100864393B1 (ko)	2003-04-10	2008-10-20	에프. 호프만-라 로슈 아게	피리미도 화합물
WO2004099209A1 (en)	2003-05-05	2004-11-18	F. Hoffmann-La-Roche Ag	Fused pyrimidine derivatives with crf activity
JP2004346145A (ja)	2003-05-21	2004-12-09	Teijin Ltd	イミド組成物およびそれからなる樹脂組成物、及びその製造方法
AU2004249120B2 (en)	2003-05-23	2008-07-24	Glaxosmithkline	Guanidino-substituted quinazolinone compounds as MC4-R agonists
EP1631295B1 (en)	2003-06-06	2010-03-03	Arexis AB	Use of condensed heterocyclic compounds as scce inhibitors for the treatment of skin diseases
IL156495A0 (en)	2003-06-17	2004-01-04	Prochon Biotech Ltd	Use of fgfr3 antagonists for treating t cell mediated diseases
EP1637523A4 (en)	2003-06-18	2009-01-07	Ube Industries	PROCESS FOR PRODUCING A PYRIMIDIN-4-ONE COMPOUND
JP2005015395A (ja)	2003-06-26	2005-01-20	Japan Science & Technology Agency	新規ピリミドピリミジンヌクレオシドとその構造類縁体
EP1660092A2 (en)	2003-07-03	2006-05-31	Myriad Genetics, Inc.	4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
AR045037A1 (es)	2003-07-10	2005-10-12	Aventis Pharma Sa	Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
BRPI0413005A (pt)	2003-07-29	2006-09-26	Irm Llc	compostos e composições como inibidores da proteìna cinase
US7390820B2 (en)	2003-08-25	2008-06-24	Amgen Inc.	Substituted quinolinone derivatives and methods of use
EP1675858A2 (en)	2003-09-03	2006-07-05	Neurogen Corporation	5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds
EP1670802A4 (en)	2003-09-18	2010-07-07	Conforma Therapeutics Corp	NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF HSP90 PROTEIN
US20070185007A1 (en)	2003-09-19	2007-08-09	Haolun Jin	Aza-quinolinol phosphonate integrase inhibitor compounds
AR045944A1 (es)	2003-09-24	2005-11-16	Novartis Ag	Derivados de isoquinolina 1.4-disustituidas
DE602004019294D1 (de)	2003-10-01	2009-03-19	Xention Ltd	Tetrahydronaphthalin- und harnstoffderivate
MXPA06003996A (es) *	2003-10-08	2006-07-05	Irm Llc	Compuestos y composiciones como inhibidores de la proteina cinasa.
US20090099165A1 (en)	2003-10-14	2009-04-16	Arizona Board Of Regents On Behalf Of The University Of Arizona	Protein Kinase Inhibitors
CN1897950A (zh)	2003-10-14	2007-01-17	惠氏公司	稠合芳基和杂芳基衍生物及其使用方法
MXPA06005578A (es)	2003-11-17	2006-08-11	Pfizer Prod Inc	Compuestos de pirrolopirimidina utiles en el tratamiento del cancer.
WO2005056524A2 (en)	2003-12-09	2005-06-23	Euro-Celtique S.A.	Therapeutic agents useful for treating pain
WO2005066162A1 (en)	2003-12-23	2005-07-21	Human Biomolecular Research Institute	Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
KR100703068B1 (ko)	2003-12-30	2007-04-05	에스케이케미칼주식회사	피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
US20050222171A1 (en)	2004-01-22	2005-10-06	Guido Bold	Organic compounds
MXPA06008257A (es)	2004-01-23	2006-08-31	Amgen Inc	Ligandos del receptor vanilloide y su uso en tratamientos.
US7902225B2 (en)	2004-01-23	2011-03-08	Janssen Pharmaceutica Nv	Mycobacterial inhibitors
US20060019952A1 (en)	2004-01-29	2006-01-26	Elixir Pharmaceuticals, Inc.	Anti-viral therapeutics
GB0402137D0 (en)	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
WO2005080393A1 (en)	2004-02-14	2005-09-01	Irm Llc	Compounds and compositions as protein kinase inhibitors
JP2007523151A (ja)	2004-02-18	2007-08-16	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	２−（ピリジン−３−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
AU2005219525B2 (en)	2004-02-27	2011-08-18	F. Hoffmann-La Roche Ag	Fused derivatives of pyrazole
WO2005085248A1 (en)	2004-02-27	2005-09-15	F.Hoffmann-La Roche Ag	Heteroaryl-fused pyrazolo derivatives
WO2005087765A1 (en)	2004-03-04	2005-09-22	Arena Pharmaceuticals, Inc.	Ligands of follicle stimulating hormone receptor and methods of use thereof
US20070197510A1 (en)	2004-03-10	2007-08-23	Kazuyuki Ohmoto	Nitriles and medicinal compositions containing the same as the active ingredient
US7763727B2 (en)	2004-03-29	2010-07-27	Mitsui Chemicals, Inc.	Compound and organic electronic device using the same
WO2005105097A2 (en) *	2004-04-28	2005-11-10	Gpc Biotech Ag	Pyridopyrimidines for treating inflammatory and other diseases
JP2005320288A (ja)	2004-05-10	2005-11-17	Mitsui Chemicals Inc	テトラカルボン酸誘導体、および該化合物を用いた電子写真感光体、電子写真装置
US20050256309A1 (en)	2004-05-12	2005-11-17	Altenbach Robert J	Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
CA2566160C (en)	2004-05-27	2011-01-18	Pfizer Products Inc.	Pyrrolopyrimidine derivatives useful in cancer treatment
JP2008501628A (ja)	2004-06-02	2008-01-24	武田薬品工業株式会社	インドール誘導体およびがんの治療用途
PE20060426A1 (es)	2004-06-02	2006-06-28	Schering Corp	DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
MXPA06014247A (es)	2004-06-10	2007-03-12	Irm Llc	Compuestos y composiciones como inhibidores de la proteina quinasa.
ATE383360T1 (de)	2004-06-11	2008-01-15	Japan Tobacco Inc	5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h- pyrido(2,3-d)pyrimidinderivate und verwandte verbindungen zur behandlung von krebs
GB0512324D0 (en)	2005-06-16	2005-07-27	Novartis Ag	Organic compounds
JP2006028027A (ja)	2004-07-12	2006-02-02	Mitsui Chemicals Inc	テトラカルボン酸誘導体、および該化合物を用いた電子写真感光体、電子写真装置
NZ553087A (en)	2004-08-31	2010-12-24	Astrazeneca Ab	Quinazolinone derivatives and their use as B-raf inhibitors
WO2006024486A2 (en)	2004-08-31	2006-03-09	F. Hoffmann-La Roche Ag	Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
US7494993B2 (en)	2004-08-31	2009-02-24	Hoffmann-La Roche Inc.	Amide derivatives of 7-amino-3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
DE102004042667A1 (de)	2004-09-01	2006-03-30	Ewald Dörken Ag	Mehrschichtige Gebäudewand
KR101165653B1 (ko)	2004-09-10	2012-07-17	우베 고산 가부시키가이샤	변성 폴리이미드 수지 및 경화가능 수지 조성물
EP1811844A4 (en)	2004-09-14	2009-12-02	Minerva Biotechnologies Corp	METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
WO2006038112A1 (en)	2004-10-01	2006-04-13	Warner-Lambert Company Llc	Use of kinase inhibitors to promote neochondrogenesis
FR2876582B1 (fr)	2004-10-15	2007-01-05	Centre Nat Rech Scient Cnrse	Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
US20060135553A1 (en)	2004-10-28	2006-06-22	Campbell David A	Imidazole derivatives
WO2006050076A1 (en)	2004-10-29	2006-05-11	Janssen Pharmaceutica, N.V.	Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
US20060110462A1 (en)	2004-11-08	2006-05-25	Pavlos Papadopoulos	Nanoparticulate compositions of tubulin inhibitor compounds
EP1824842A4 (en)	2004-11-18	2009-08-26	Incyte Corp	INHIBITORS OF 11-HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHOD OF USE
ZA200704888B (en)	2004-11-22	2009-02-25	Vertex Pharma	Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
RU2007123675A (ru)	2004-11-24	2008-12-27	Новартис АГ (CH)	Комбинации ингибиторов jak
MY140748A (en)	2004-12-06	2010-01-15	Astrazeneca Ab	Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
CA2590294A1 (en)	2004-12-13	2006-06-22	Sunesis Pharmaceuticals, Inc.	Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US20100152206A1 (en)	2005-01-07	2010-06-17	Ralph Mazitschek	Bicyclic Dihydropyrimidines and Uses Thereof
DE102005008310A1 (de)	2005-02-17	2006-08-24	Schering Ag	Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
BRPI0607402A2 (pt)	2005-03-01	2009-09-01	Pfizer Ltd	uso de inibidores de pde7 para o tratamento de dor neuropática
US7297700B2 (en)	2005-03-24	2007-11-20	Renovis, Inc.	Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
CA2610292C (en)	2005-03-30	2015-06-02	Minerva Biotechnologies Corporation	Proliferation of muc1 expressing cells
JP2006284843A (ja)	2005-03-31	2006-10-19	Mitsui Chemicals Inc	テトラカルボン酸誘導体を用いた電子写真感光体、電子写真装置
US20060223993A1 (en)	2005-04-01	2006-10-05	Connor Daniel M	Colorant compounds, intermediates, and compositions
JP2006316054A (ja)	2005-04-15	2006-11-24	Tanabe Seiyaku Co Ltd	高コンダクタンス型カルシウム感受性ｋチャネル開口薬
KR100781704B1 (ko)	2005-04-20	2007-12-03	에스케이케미칼주식회사	피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
EP1885369B1 (en)	2005-05-04	2015-09-23	Evotec AG	Fused heterocyclic compounds, and compositions and uses thereof
CA2607147C (en)	2005-05-09	2018-07-17	Ono Pharmaceutical Co., Ltd.	Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2006124731A2 (en) *	2005-05-12	2006-11-23	Irm Llc	Compounds and compositions as protein kinase inhibitors
CN101175753B (zh)	2005-05-13	2011-03-23	Irm责任有限公司	作为蛋白激酶抑制剂的化合物和组合物
WO2006135821A2 (en)	2005-06-09	2006-12-21	Achille Carlisle Tisdelle	Vehicular head and neck safety system and method
GB0512844D0 (en)	2005-06-23	2005-08-03	Novartis Ag	Organic compounds
UA99701C2 (ru)	2005-07-01	2012-09-25	Медарекс, Инк.	Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1)
JP2009502801A (ja)	2005-07-22	2009-01-29	サネシスファーマシューティカルズ，インコーポレイテッド	Ａｕｒｏｒａキナーゼインヒビターとして有用なピラゾロピリミジン
ES2270715B1 (es)	2005-07-29	2008-04-01	Laboratorios Almirall S.A.	Nuevos derivados de pirazina.
EP1910369A1 (en)	2005-07-29	2008-04-16	Astellas Pharma Inc.	Fused heterocycles as lck inhibitors
KR20080033526A (ko)	2005-08-09	2008-04-16	아이알엠 엘엘씨	단백질 키나제 억제제로서의 화합물 및 조성물
EP1919924A2 (en)	2005-08-16	2008-05-14	Irm, Llc	Compounds and compositions as protein kinase inhibitors
EP1919470A1 (en)	2005-08-25	2008-05-14	F.Hoffmann-La Roche Ag	FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS
US7678917B2 (en)	2005-09-01	2010-03-16	Hoffman-La Roche Inc.	Factor Xa inhibitors
KR20080045266A (ko)	2005-09-06	2008-05-22	스미스클라인 비참 코포레이션	벤즈이미다졸 티오펜을 제조하기 위한 위치선택적인 방법
US8193356B2 (en)	2005-09-15	2012-06-05	Aska Pharmaceutical Co., Ltd.	Heterocycle compound, and production process and application thereof
US20070116984A1 (en)	2005-09-21	2007-05-24	Doosan Corporation	Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same
WO2007038209A2 (en)	2005-09-23	2007-04-05	Schering Corporation	Fused tetracyclic mglur1 antagonists as therapeutic agents
DE102005048072A1 (de)	2005-09-24	2007-04-05	Bayer Cropscience Ag	Thiazole als Fungizide
EA201200669A1 (ru)	2005-10-07	2012-11-30	Экселиксис, Инк.	ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
AU2006302179C1 (en)	2005-10-07	2013-06-20	Exelixis, Inc.	N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
WO2007061554A2 (en)	2005-10-21	2007-05-31	Purdue Research Foundation	Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries
JP2009513603A (ja)	2005-10-26	2009-04-02	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｍｃｈ拮抗活性を有する（ヘテロ）アリール化合物及びこの化合物を含む医薬
BR122021011788B1 (pt)	2005-11-01	2022-01-25	Impact Biomedicines, Inc	Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
US8067457B2 (en)	2005-11-01	2011-11-29	Millennium Pharmaceuticals, Inc.	Compounds useful as antagonists of CCR2
US8604042B2 (en)	2005-11-01	2013-12-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
CA2627839C (en)	2005-11-02	2014-08-19	Bayer Healthcare Ag	Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
WO2007056075A2 (en)	2005-11-02	2007-05-18	Targegen, Inc.	Six membered heteroaromatic inhibitors targeting resistant kinase mutations
DK1954274T3 (da)	2005-11-10	2011-01-31	Chemocentryx Inc	Substituerede quinoloner og fremgangsmåder til anvendelse
JP4371164B2 (ja)	2005-11-10	2009-11-25	萬有製薬株式会社	アザ置換スピロ誘導体
WO2007058626A1 (en)	2005-11-16	2007-05-24	S*Bio Pte Ltd	Indazole compounds
WO2007058392A1 (ja)	2005-11-21	2007-05-24	Japan Tobacco Inc.	ヘテロ環化合物およびその医薬用途
PE20070855A1 (es)	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
BRPI0619146A2 (pt)	2005-12-02	2011-09-13	Bayer Pharmaceuticals Corp	derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
JP2009519908A (ja)	2005-12-08	2009-05-21	ミレニアム・ファーマシューティカルズ・インコーポレイテッド	キナーゼ阻害活性を有する二環式化合物
WO2007066189A2 (en)	2005-12-09	2007-06-14	Pfizer Products Inc.	Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
US20080318989A1 (en)	2005-12-19	2008-12-25	Burdick Daniel J	Pyrimidine Kinase Inhibitors
EP1976847B1 (en)	2005-12-21	2015-06-17	Novartis AG	Pyrimidinyl aryl urea derivatives being fgf inhibitors
US7998959B2 (en)	2006-01-12	2011-08-16	Incyte Corporation	Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
UY30118A1 (es)	2006-01-31	2007-06-29	Tanabe Seiyaku Co	Compueto amina trisustituido
WO2007092879A2 (en)	2006-02-08	2007-08-16	Janssen Pharmaceutica, N.V.	Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
KR20080085232A (ko)	2006-02-17	2008-09-23	화이자 리미티드	Ｔｌｒ7 조절제로서 3-데아자퓨린 유도체
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US8349850B2 (en)	2006-03-28	2013-01-08	Atir Holding S.A.	Heterocyclic compounds and uses thereof in the treatment of sexual disorders
BRPI0709699A2 (pt)	2006-03-29	2011-07-26	Foldrx Pharmaceuticals Inc	inibiÇço da toxidez da alfa-sinucleina
EP2046737B1 (en)	2006-04-06	2011-09-07	Wisconsin Alumni Research Foundation	2-methylene-1 alpha,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof
EP2010534A4 (en)	2006-04-13	2010-08-18	Astrazeneca Ab	THIOXANTHINE DERIVATIVES AND THEIR USE AS DFO INHIBITORS
GB0608386D0 (en)	2006-04-27	2006-06-07	Senexis Ltd	Compounds
CA2651072A1 (en)	2006-05-01	2007-11-08	Pfizer Products Inc.	Substituted 2-amino-fused heterocyclic compounds
JP5241704B2 (ja)	2006-05-11	2013-07-17	アイアールエム・リミテッド・ライアビリティ・カンパニー	プロテインキナーゼ阻害剤としての化合物および組成物
RU2008149245A (ru)	2006-05-15	2010-06-20	Айрм Ллк (Bm)	Композиции и способы ингибирования рецепторных киназ fgf
WO2007143600A2 (en)	2006-06-05	2007-12-13	Incyte Corporation	Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
DE102006027156A1 (de)	2006-06-08	2007-12-13	Bayer Schering Pharma Ag	Sulfimide als Proteinkinaseinhibitoren
WO2007147217A1 (en)	2006-06-22	2007-12-27	Prana Biotechnology Limited	Method of treatment of glioma brain tumour
WO2008001070A1 (en)	2006-06-30	2008-01-03	Astrazeneca Ab	Pyrimidine derivatives useful in the treatment of cancer
US20090281115A1 (en)	2006-06-30	2009-11-12	Board of Regents, The University of Texas System, a Texas University	Inhibitors of c-kit and uses thereof
JP2009542604A (ja)	2006-07-06	2009-12-03	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	４−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用
US8030487B2 (en)	2006-07-07	2011-10-04	Targegen, Inc.	2-amino—5-substituted pyrimidine inhibitors
TW200811134A (en)	2006-07-12	2008-03-01	Irm Llc	Compounds and compositions as protein kinase inhibitors
WO2008012635A2 (en)	2006-07-26	2008-01-31	Pfizer Products Inc.	Amine derivatives useful as anticancer agents
WO2008021851A2 (en)	2006-08-09	2008-02-21	Smithkline Beecham Corporation	Novel compounds as antagonists or inverse agonists for opioid receptors
JP2010500994A (ja)	2006-08-16	2010-01-14	エグゼリクシス，インコーポレイテッド	Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法
DE102006041382A1 (de)	2006-08-29	2008-03-20	Bayer Schering Pharma Ag	Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
CA2974246C (en)	2006-09-01	2020-02-25	Senhwa Biosciences, Inc.	Tricyclic heteroaryl compounds and their use as protein modulators
WO2008079460A2 (en)	2006-09-05	2008-07-03	Emory University	Tyrosine kinase inhibitors for prevention or treatment of infection
JP2010502751A (ja)	2006-09-11	2010-01-28	シージーアイファーマシューティカルズ，インコーポレイティド	キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
US7897762B2 (en)	2006-09-14	2011-03-01	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of proliferative diseases
CA2664095A1 (en)	2006-09-21	2008-03-27	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
EP2069341B1 (en)	2006-09-22	2010-12-29	Glaxo Group Limited	Pyrrolo[2, 3-b]pyridin-4-yl-benzenesulfonamide compounds as ikk2 inhibitors
EP2074127A1 (en)	2006-09-28	2009-07-01	Novartis AG	Pyrazolo [1, 5-a]pyrimidine derivatives and their therapeutic use
CN103739595A (zh)	2006-10-02	2014-04-23	Irm责任有限公司	作为蛋白激酶抑制剂的化合物和组合物
WO2008052934A1 (en)	2006-10-30	2008-05-08	Glaxo Group Limited	Novel substituted pyrimidines as cysteine protease inhibitors
US7858645B2 (en)	2006-11-01	2010-12-28	Hoffmann-La Roche Inc.	Indazole derivatives
JP5244118B2 (ja)	2006-11-10	2013-07-24	ブリストル−マイヤーズスクイブカンパニー	新規キナーゼ阻害剤
WO2008063583A1 (en)	2006-11-17	2008-05-29	Polyera Corporation	Acene-based organic semiconductor materials and methods of preparing and using the same
WO2008063609A2 (en)	2006-11-17	2008-05-29	Polyera Corporation	Diimide-based semiconductor materials and methods of preparing and using the same
KR20080045536A (ko)	2006-11-20	2008-05-23	에스케이케미칼주식회사	피리딘 화합물을 포함하는 간염 치료 및 예방 또는 간 보호효능을 갖는 약제 조성물
RS57741B1 (sr)	2006-11-22	2018-12-31	Incyte Holdings Corp	Imidazotriazini i imidazopirimidini kao inhibitori kinaze
MX2009006466A (es)	2006-12-13	2009-06-26	Schering Corp	Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
WO2008071455A1 (en)	2006-12-15	2008-06-19	Bayer Schering Pharma Aktiengesellschaft	Bicyclic acyltryptophanols
WO2008074068A1 (en)	2006-12-20	2008-06-26	Prana Biotechnology Limited	Substituted quinoline derivatives as antiamyloidogeneic agents
US7737149B2 (en)	2006-12-21	2010-06-15	Astrazeneca Ab	N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
JP5442448B2 (ja)	2006-12-22	2014-03-12	アステックス、セラピューティックス、リミテッド	Ｆｇｆｒインヒビターとしての二環式ヘテロ環式化合物
CA2672213C (en)	2006-12-22	2016-02-16	Astex Therapeutics Limited	Bicyclic amine derivatives as protein tyrosine kinase inhibitors
EA200900799A1 (ru)	2006-12-22	2009-12-30	Новартис Аг	Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями
FR2911140B1 (fr)	2007-01-05	2009-02-20	Sanofi Aventis Sa	Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
EP2104676A2 (en)	2007-01-08	2009-09-30	Polyera Corporation	Methods for preparing arene-bis(dicarboximide)-based semiconducting materials and related intermediates for preparing same
CN101007778A (zh)	2007-01-10	2007-08-01	复旦大学	一种链延长型芴基双马来酰亚胺及其制备方法
ES2390188T3 (es)	2007-01-12	2012-11-07	Biocryst Pharmaceuticals, Inc.	Análogos de nucleósidos antivirales
MX2009007426A (es)	2007-01-12	2009-07-17	Astellas Pharma Inc	Compuesto de piridina condensado.
FR2911604B1 (fr)	2007-01-19	2009-04-17	Sanofi Aventis Sa	Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
JP5358962B2 (ja)	2007-02-06	2013-12-04	住友化学株式会社	組成物及び該組成物を用いてなる発光素子
JP2008198769A (ja)	2007-02-13	2008-08-28	Nippon Steel Chem Co Ltd	有機エレクトロルミネッセント素子
US8633211B2 (en)	2007-03-06	2014-01-21	Novartis Ag	Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions
EP2139887A2 (en)	2007-03-07	2010-01-06	Alantos Pharmaceuticals Holding, Inc.	Metalloprotease inhibitors containing a heterocyclic moiety
RS54533B1 (en)	2007-03-12	2016-06-30	Ym Biosciences Australia Pty Ltd	PHENYL AMINOPYRIMIDINE COMPOUNDS AND THEIR APPLICATIONS
US20080234262A1 (en)	2007-03-21	2008-09-25	Wyeth	Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
AU2007227278B2 (en)	2007-03-21	2014-09-11	Epix Pharmaceuticals, Inc.	SIP receptor modulating compounds and use thereof
EP2132207A2 (en)	2007-03-23	2009-12-16	Amgen Inc.	Heterocyclic compounds and their uses
EP2896624B1 (en)	2007-03-28	2016-07-13	Atir Holding S.A.	Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
KR20080091948A (ko)	2007-04-10	2008-10-15	에스케이케미칼주식회사	락탐형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물
KR20100016477A (ko)	2007-04-12	2010-02-12	어드밴스드 테크놀러지 머티리얼즈, 인코포레이티드	Ａｌｄ/ｃｖｄ용의 지르코늄, 하프늄, 티타늄 및 규소 전구체
MX2009011359A (es)	2007-04-20	2009-11-05	Schering Corp	Derivados de pirimidinona y sus metodos de uso.
EP1985612A1 (en)	2007-04-26	2008-10-29	Bayer Schering Pharma Aktiengesellschaft	Arymethylen substituted N-Acyl-gamma-aminoalcohols
EP1990342A1 (en)	2007-05-10	2008-11-12	AEterna Zentaris GmbH	Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
CL2008001356A1 (es)	2007-05-10	2008-11-14	Smithkline Beecham Corp	Compuestos derivados de quinoxalina, inhibidores de la pi3 quinasa _(p13ka, pi3ko, pi3b y/o pi3ky); composicion farmaceutica; uso para tratar un trastorno autoinmune, enfermedad inflamatoria, cardiovascular, neurodegerativa, alergia, asma, enfermedad renal, cancer, rechazo de transplante, lesiones pulmonares.
WO2008144253A1 (en)	2007-05-14	2008-11-27	Irm Llc	Protein kinase inhibitors and methods for using thereof
GB2449293A (en)	2007-05-17	2008-11-19	Evotec	Compounds having Hsp90 inhibitory activity
BRPI0812363A2 (pt)	2007-06-03	2015-02-03	Univ Vanderbilt	Moduladores alostéricos positivos de mglurs de benzamida e métodos de preparação e utilização dos mesmos
US8163752B2 (en)	2007-06-07	2012-04-24	Merck, Sharp & Dohme Corp.	Tricyclic anilide heterocyclic CGRP receptor antagonists
US8633186B2 (en)	2007-06-08	2014-01-21	Senomyx Inc.	Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en)	2007-06-08	2011-04-19	Senomyx, Inc.	Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
LT2168966T (lt)	2007-06-15	2017-01-10	Msd K.K.	Bicikloanilino darinys
US8354509B2 (en)	2007-06-18	2013-01-15	Msd Oss B.V.	Antibodies to human programmed death receptor PD-1
AU2008280135B2 (en)	2007-07-26	2012-02-23	Novartis Ag	Organic compounds
EP2018859A1 (en)	2007-07-26	2009-01-28	Bayer Schering Pharma Aktiengesellschaft	Arylmethylene substituted N-acyl-beta-amino alcohols
EP2020404A1 (en)	2007-08-01	2009-02-04	Bayer Schering Pharma Aktiengesellschaft	Cyanomethyl substituted N-Acyl Tryptamines
EP2173354A4 (en)	2007-08-09	2011-10-05	Glaxosmithkline Llc	CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS
WO2009019518A1 (en)	2007-08-09	2009-02-12	Astrazeneca Ab	Pyrimidine compounds having a fgfr inhibitory effect
WO2009029625A1 (en)	2007-08-27	2009-03-05	Kalypsys, Inc.	4- [heterocyclyl-methyl] -8-fluoro-quinolin-2-ones useful as nitric oxide synthase inhibitors
US7960400B2 (en)	2007-08-27	2011-06-14	Duquesne University Of The Holy Ghost	Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
PT2200436E (pt)	2007-09-04	2015-04-29	Scripps Research Inst	Pirimidinilaminas substituídas como inibidoras da proteína quinase
WO2009030871A1 (en)	2007-09-07	2009-03-12	Vernalis R & D Ltd	Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
TW200920357A (en)	2007-09-10	2009-05-16	Curis Inc	HSP90 inhibitors containing a zinc binding moiety
RU2501803C2 (ru)	2007-10-01	2013-12-20	Айзис Фармасьютикалз, Инк.	Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4)
JP5470043B2 (ja)	2007-10-05	2014-04-16	Ｍｓｄ株式会社	ベンゾオキサジノン誘導体
US20100298289A1 (en)	2007-10-09	2010-11-25	Ucb Pharma, S.A.	Heterobicyclic compounds as histamine h4-receptor antagonists
WO2009049018A1 (en)	2007-10-10	2009-04-16	Syndax Pharmaceuticals, Inc.	Novel compounds and methods of using them
CN101821243B (zh)	2007-10-11	2013-05-08	中国科学院上海药物研究所	一类嘧啶取代苯丙酸衍生物及其作为ppar激动剂的用途
GB0720041D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New Compounds
GB0720038D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New compounds
WO2009047993A1 (ja)	2007-10-13	2009-04-16	Konica Minolta Holdings, Inc.	有機エレクトロルミネッセンス素子、表示装置及び照明装置
EA201000484A1 (ru)	2007-10-16	2010-12-30	ВАЙЕТ ЭлЭлСи	Тиенопиримидиновые и пиразолопиримидиновые соединения и их применение в качестве ингибиторов киназы mtor и киназы pi3
EA201000615A1 (ru)	2007-10-17	2010-12-30	Новартис Аг	Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
CA2703653A1 (en)	2007-10-25	2009-04-30	Astrazeneca Ab	Pyridine and pyrazine derivatives -083
RU2007139634A (ru)	2007-10-25	2009-04-27	Сергей Олегович Бачурин (RU)	Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
WO2009056886A1 (en)	2007-11-01	2009-05-07	Astrazeneca Ab	Pyrimidine derivatives and their use as modulators of fgfr activity
CN101917849B (zh)	2007-11-28	2014-11-05	达那-法伯癌症研究所	Bcr-abl的小分子豆蔻酸酯抑制剂及其使用方法
CA2707653A1 (en)	2007-12-03	2009-06-11	Boehringer Ingelheim International Gmbh	Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
EA201001030A1 (ru)	2007-12-19	2011-02-28	Амген Инк.	Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
AU2008345225A1 (en)	2007-12-21	2009-07-09	University Of Rochester	Method for altering the lifespan of eukaryotic organisms
CA2710458A1 (en)	2007-12-21	2009-07-09	Wyeth Llc	Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
WO2009086509A2 (en)	2007-12-27	2009-07-09	Purdue Research Foundation	Reagents for biomolecular labeling, detection and quantification employing raman spectroscopy
FR2926297B1 (fr)	2008-01-10	2013-03-08	Centre Nat Rech Scient	Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
EP2238144A1 (en)	2008-01-24	2010-10-13	UCB Pharma, S.A.	Compounds comprising a cyclobutoxy group
US8629154B2 (en)	2008-01-24	2014-01-14	Andrey Alexandrovich Ivashchenko	Substituted cycloalcano[e and d] pyrazolo [1,5-a]pyrimidines/antagonists of serotonin 5-HT6 receptors and methods for production and the use thereof
KR20100119776A (ko)	2008-01-24	2010-11-10	알라 캠, 엘엘씨	2-알킬아미노-3-아릴설포닐-사이클로알카노[ｅ 또는 ｄ]피라졸로[1,5-Ａ]피리미딘/세로토닌 5-ＨＴ6 수용체의 길항제, 이의 제조방법 및 이의 용도
NZ586695A (en)	2008-01-25	2011-12-22	High Point Pharmaceuticals Llc	TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-alpha SYNTHESIS AND AS PDE4 INHIBITORS
US8987280B2 (en)	2008-01-30	2015-03-24	Genentech, Inc.	Pyrazolopyrimidine PI3K inhibitor compounds and methods of use
EP2265270A1 (en)	2008-02-04	2010-12-29	OSI Pharmaceuticals, Inc.	2-aminopyridine kinase inhibitors
US20110190263A1 (en)	2008-02-22	2011-08-04	Irm Llc	Compounds and compositions as modulators of gpr119 activity
AU2009216851B2 (en)	2008-02-22	2013-11-07	F. Hoffmann-La Roche Ag	Modulators for amyloid beta
WO2009108332A1 (en)	2008-02-27	2009-09-03	Vitae Pharmaceuticals, Inc.	INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1
WO2009108827A1 (en)	2008-02-29	2009-09-03	Wyeth	Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
ITTV20080039A1 (it)	2008-03-06	2009-09-07	Alpinestars Research Srl	Collare di protezione in particolare per guidatori di motoveicoli
WO2009114335A2 (en)	2008-03-12	2009-09-17	Merck & Co., Inc.	Pd-1 binding proteins
GB0804701D0 (en)	2008-03-13	2008-04-16	Amura Therapeutics Ltd	Compounds
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en)	2008-03-14	2009-09-17	Intellikine, Inc.	Kinase inhibitors and methods of use
US20090246198A1 (en)	2008-03-31	2009-10-01	Takeda Pharmaceutical Company Limited	Mapk/erk kinase inhibitors and methods of use thereof
US20100056524A1 (en)	2008-04-02	2010-03-04	Mciver Edward Giles	Compound
US8436005B2 (en)	2008-04-03	2013-05-07	Abbott Laboratories	Macrocyclic pyrimidine derivatives
JP5530422B2 (ja)	2008-04-07	2014-06-25	アムジエン・インコーポレーテツド	細胞周期阻害薬としてのｇｅｍ−二置換およびスピロ環式アミノピリジン／ピリミジン
WO2009124755A1 (en)	2008-04-08	2009-10-15	European Molecular Biology Laboratory (Embl)	Compounds with novel medical uses and method of identifying such compounds
WO2009125808A1 (ja)	2008-04-11	2009-10-15	第一三共株式会社	アミノシクロヘキシル誘導体
WO2009125809A1 (ja)	2008-04-11	2009-10-15	第一三共株式会社	ピペリジン誘導体
EP2444403A1 (en)	2008-04-18	2012-04-25	Shionogi Co., Ltd.	Heterocyclic compound having inhibitory activity on PI3K
AU2009238590A1 (en)	2008-04-22	2009-10-29	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
US8309577B2 (en)	2008-04-23	2012-11-13	Bristol-Myers Squibb Company	Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US7863291B2 (en)	2008-04-23	2011-01-04	Bristol-Myers Squibb Company	Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2009133101A1 (en)	2008-04-29	2009-11-05	Novartis Ag	Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
WO2009132980A1 (en)	2008-04-29	2009-11-05	F. Hoffmann-La Roche Ag	Pyrimidinyl pyridone inhibitors of jnk.
WO2009133127A1 (en)	2008-04-30	2009-11-05	Merck Serono S.A.	Fused bicyclic compounds and use thereof as pi3k inhibitors
US9315449B2 (en)	2008-05-15	2016-04-19	Duke University	Substituted pyrazoles as heat shock transcription factor activators
MY155535A (en)	2008-05-23	2015-10-30	Novartis Ag	Derivatives of quinolines and quinoxalines as protien tyrosine kinase inhibitors
WO2009144205A1 (en)	2008-05-30	2009-12-03	Basf Se	Rylene-based semiconductor materials and methods of preparation and use thereof
EP2303269B1 (en)	2008-06-03	2014-07-30	Merck Sharp & Dohme Corp.	Inhibitors of akt activity
KR101656793B1 (ko)	2008-06-10	2016-09-12	유디씨 아일랜드 리미티드	신규한 전이 금속 착물 및 이의 유기 발광 다이오드에서의 용도 - ⅲ
FR2932600B1 (fr)	2008-06-11	2010-06-04	Areva Np	Embout inferieur d'assemblage de combustible nucleaire
US8507504B2 (en)	2008-06-12	2013-08-13	Merck Sharp & Dohme Corp.	Process for producing bicycloaniline derivatives
GB0810902D0 (en)	2008-06-13	2008-07-23	Astex Therapeutics Ltd	New compounds
BRPI0914233A2 (pt)	2008-06-19	2015-11-03	Astrazeneca Ab	composto, uso de um composto, métodos para produzir um efeito inibidor de fgfr e para produzir um efeito anticâncer em um animal de sangue quente, composição farmacêutica, e, método para tratar uma doença
US8575337B2 (en)	2008-06-24	2013-11-05	Research Foundation Itsuu Laboratory	Oxazolidinone derivative having fused ring
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ590320A (en)	2008-07-14	2012-12-21	Gilead Sciences Inc	Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
WO2010007099A1 (en)	2008-07-15	2010-01-21	Cellzome Limited	2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
CA2726460C (en)	2008-07-15	2017-02-21	F. Hoffmann-La Roche Ag	Novel phenyl-imidazopyridines and pyridazines
UY31982A (es)	2008-07-16	2010-02-26	Boehringer Ingelheim Int	Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
CA2730610A1 (en)	2008-07-16	2010-01-21	Schering Corporation	Bicyclic heterocycle derivatives and their use as gpcr modulators
US8822480B2 (en)	2008-07-16	2014-09-02	Merck Sharp & Dohme Corp.	Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
US10722562B2 (en)	2008-07-23	2020-07-28	Immudex Aps	Combinatorial analysis and repair
WO2010017047A1 (en)	2008-08-05	2010-02-11	Merck & Co., Inc.	Therapeutic compounds
WO2010015643A1 (en)	2008-08-06	2010-02-11	Novartis Ag	New antiviral modified nucleosides
JP2011530596A (ja)	2008-08-11	2011-12-22	プレジデントアンドフェロウズオブハーバードカレッジ	ｔＲＮＡ合成酵素の阻害のためのハロフジノン類似体およびそれらの使用
UY32049A (es)	2008-08-14	2010-03-26	Takeda Pharmaceutical	Inhibidores de cmet
US20110166135A1 (en)	2008-09-10	2011-07-07	Hiroshi Morimoto	Aromatic nitrogen-containing 6-membered ring compounds and their use
US8552154B2 (en)	2008-09-26	2013-10-08	Emory University	Anti-PD-L1 antibodies and uses therefor
AR073760A1 (es)	2008-10-03	2010-12-01	Astrazeneca Ab	Derivados heterociclicos y metodos de uso de los mismos
WO2010045371A1 (en)	2008-10-15	2010-04-22	Gilead Palo Alto, Inc.	Pyrido- and pyrimido (1, 2-a) pyrimidine compounds useful as stearoyl coa desaturase inhibitors
US8110578B2 (en)	2008-10-27	2012-02-07	Signal Pharmaceuticals, Llc	Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US20100105655A1 (en)	2008-10-29	2010-04-29	Astrazeneca Ab	Novel compounds 515
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
WO2010052448A2 (en)	2008-11-05	2010-05-14	Ucb Pharma S.A.	Fused pyrazine derivatives as kinase inhibitors
WO2010059552A1 (en)	2008-11-18	2010-05-27	Glaxosmithkline Llc	Prolyl hydroxylase inhibitors
JP5743897B2 (ja)	2008-11-20	2015-07-01	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅＬＬＣ	化合物
WO2010064621A1 (ja)	2008-12-03	2010-06-10	コニカミノルタホールディングス株式会社	有機エレクトロルミネッセンス素子、有機エレクトロルミネッセンス素子材料、表示装置及び照明装置
KR101061599B1 (ko)	2008-12-05	2011-09-02	한국과학기술연구원	비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
RU2586212C2 (ru)	2008-12-08	2016-06-10	Мандифарма Интернэшнл Корпорейшн Лимитед	Композиции ингибиторов тирозинкиназных рецепторов белков
US8110265B2 (en)	2008-12-09	2012-02-07	The Coca-Cola Company	Pet container and compositions having enhanced mechanical properties and gas barrier properties
RU2636023C2 (ru)	2008-12-09	2017-11-17	Дженентек, Инк.	Антитела к pd-l1 и их применение для усиления функции т-клеток
WO2010067888A1 (en)	2008-12-12	2010-06-17	Banyu Pharmaceutical Co.,Ltd.	Dihydropyrimidopyrimidine derivatives
EP2376493B1 (en)	2008-12-12	2016-10-05	Msd K.K.	Dihydropyrimidopyrimidine derivative
CA2747170C (en)	2008-12-19	2017-07-18	Abbott Laboratories	Tetrahydroisoquinoline derivatives and their uses to treat cancers and autoimmune disorders
JO2885B1 (en)	2008-12-22	2015-03-15	ايلي ليلي اند كومباني	Protein kinase inhibitors
AU2009335016A1 (en)	2008-12-30	2011-08-18	Arqule, Inc.	Substituted pyrazolo [3, 4-b] pyridine compounds
CN102325755B (zh)	2008-12-30	2015-07-01	艾科尔公司	取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
JP5908728B2 (ja)	2009-01-06	2016-04-26	ダナファーバーキャンサーインスティテュートインコーポレイテッド	ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法
JOP20190230A1 (ar)	2009-01-15	2017-06-16	Incyte Corp	طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
WO2010083145A1 (en)	2009-01-16	2010-07-22	Merck Sharp & Dohme Corp.	IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS
DE102009007038A1 (de)	2009-02-02	2010-08-05	Merck Patent Gmbh	Metallkomplexe
JP2010180147A (ja)	2009-02-04	2010-08-19	Mitsubishi Gas Chemical Co Inc	シアン酸エステル化合物、およびその硬化物
EP2393835B1 (en)	2009-02-09	2017-04-05	Université d'Aix-Marseille	Pd-1 antibodies and pd-l1 antibodies and uses thereof
TW201038569A (en)	2009-02-16	2010-11-01	Abbott Gmbh & Co Kg	Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
TW201035102A (en)	2009-03-04	2010-10-01	Gruenethal Gmbh	Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
US20100278835A1 (en)	2009-03-10	2010-11-04	Astrazeneca Uk Limited	Novel compounds 660
WO2010104047A1 (ja)	2009-03-11	2010-09-16	国立大学法人京都大学	多環芳香族化合物
AR076126A1 (es)	2009-03-18	2011-05-18	Schering Corp	Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa
US8491869B2 (en)	2009-03-23	2013-07-23	Eli Lilly And Company	Imaging agents for detecting neurological disorders
ES2540119T3 (es)	2009-03-27	2015-07-08	Abbvie Inc.	Compuestos como ligandos de receptores cannabinoides
WO2010117425A1 (en)	2009-03-31	2010-10-14	Biogen Idec Ma Inc.	Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
US8481525B2 (en)	2009-04-06	2013-07-09	University Of Health Network	Kinase inhibitors and method of treating cancer with same
CN102459246B (zh)	2009-04-07	2014-05-07	阿斯利康(瑞典)有限公司	作为治疗剂的异噁唑-3(2h)-酮类似物
GB0906472D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
GB0906470D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
JP5531446B2 (ja)	2009-04-20	2014-06-25	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、有機エレクトロルミネッセンス素子材料、表示装置および照明装置
ES2347630B1 (es)	2009-04-29	2011-09-08	Universitat Ramon Llull	Sintesis y usos de 4-cianopentanoatos y 4-cianopentenoatos sustituidos.
EP2424368B1 (en)	2009-04-29	2014-12-31	Locus Pharmaceuticals, Inc.	Pyrrolotriazine compounds
US20100280067A1 (en)	2009-04-30	2010-11-04	Pakala Kumara Savithru Sarma	Inhibitors of acetyl-coa carboxylase
JO2860B1 (en)	2009-05-07	2015-03-15	ايلي ليلي اند كومباني	Phenylendazolyl compounds
JP5600891B2 (ja)	2009-05-15	2014-10-08	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置および照明装置
JP5604808B2 (ja)	2009-05-20	2014-10-15	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP5568889B2 (ja)	2009-05-22	2014-08-13	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置、照明装置及び有機エレクトロルミネッセンス素子材料
JP5629980B2 (ja)	2009-05-22	2014-11-26	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置及び照明装置
US8637465B2 (en)	2009-05-27	2014-01-28	Kobenhavns Universitet	Fibroblast growth factor receptor-derived peptides binding to NCAM
JP5499519B2 (ja)	2009-05-27	2014-05-21	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置及び照明装置
GB0910003D0 (en)	2009-06-11	2009-07-22	Univ Leuven Kath	Novel compounds for the treatment of neurodegenerative diseases
JP5600894B2 (ja)	2009-06-24	2014-10-08	コニカミノルタ株式会社	白色有機エレクトロルミネッセンス素子、表示装置及び照明装置
SI2445502T1 (sl)	2009-06-25	2017-10-30	Alkermes Pharma Ireland Limited	Heterociklične spojine za zdravljenje neuroloških in psiholoških motenj
US8883888B2 (en)	2009-06-30	2014-11-11	Zeon Corporation	Diarylamine compounds, aging inhibitor, polymer composition, crosslinked rubber product and molded article of the crosslinked product, and method of producing diarylamine compound
WO2011007819A1 (ja)	2009-07-17	2011-01-20	塩野義製薬株式会社	ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
US8680077B2 (en)	2009-07-24	2014-03-25	Duke University	Prochelators useful for inhibiting metal-associated toxicity
FR2948568B1 (fr)	2009-07-30	2012-08-24	Sanofi Aventis	Formulation pharmaceutique
TWI468402B (zh)	2009-07-31	2015-01-11	必治妥美雅史谷比公司	降低β－類澱粉生成之化合物
KR20120092567A (ko)	2009-08-05	2012-08-21	벌시테크 리미티드	항바이러스 화합물 및 이를 제조하는 방법 및 이의 이용 방법
JP2012197231A (ja)	2009-08-06	2012-10-18	Oncotherapy Science Ltd	Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
HRP20151258T1 (hr)	2009-08-07	2016-02-26	Chugai Seiyaku Kabushiki Kaisha	Derivat aminopirazola
WO2011018894A1 (en)	2009-08-10	2011-02-17	Raqualia Pharma Inc.	Pyrrolopyrimidine derivatives as potassium channel modulators
TR201900259T4 (tr)	2009-08-17	2019-02-21	Intellikine Llc	Heterosiklik Bileşikler Ve Bunların Kullanımları
JP5577650B2 (ja)	2009-08-24	2014-08-27	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、有機エレクトロルミネッセンス素子材料、表示装置及び照明装置
KR101184115B1 (ko)	2009-08-31	2012-09-18	일동제약주식회사	신규 펩티드 데포르밀라제 저해제 화합물 및 그 제조방법
ES2534226T3 (es)	2009-09-03	2015-04-20	Bioenergenix	Compuestos heterocíclicos para la inhibición de PASK
EP2473498A1 (en)	2009-09-04	2012-07-11	Bayer Pharma Aktiengesellschaft	Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
WO2011031740A1 (en)	2009-09-09	2011-03-17	Achaogen, Inc.	Antibacterial fluoroquinolone analogs
US9481675B2 (en)	2009-09-11	2016-11-01	Merck Sharp & Dohme Corp.	Gyrase inhibitors
WO2011035376A1 (en)	2009-09-24	2011-03-31	Romar Engineering Pty Ltd	A mould or mould core and a method of manufacturing a mould or mould core
WO2011041143A1 (en)	2009-10-01	2011-04-07	Merck Sharp & Dohme Corp.	HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US8466155B2 (en)	2009-10-02	2013-06-18	Boehringer Ingelheim International Gmbh	Pyrimidines
GB0917571D0 (en)	2009-10-07	2009-11-25	Karobio Ab	Novel estrogen receptor ligands
EP2308866A1 (de)	2009-10-09	2011-04-13	Bayer CropScience AG	Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
FR2951172B1 (fr)	2009-10-13	2014-09-26	Pf Medicament	Derives pyrazolopyridines en tant qu'agent anticancereux
WO2011049988A2 (en)	2009-10-20	2011-04-28	Eiger Biopharmaceuticals, Inc.	Indazoles to treat flaviviridae virus infection
KR20110043270A (ko)	2009-10-21	2011-04-27	(주)씨에스엘쏠라	유기발광화합물 및 이를 구비한 유기발광소자
AP3103A (en)	2009-10-22	2015-01-31	Gilead Sciences Inc	Derivatives of purine or deazapurine useful for the treatment of (inter alia)viral infections
WO2011050245A1 (en)	2009-10-23	2011-04-28	Yangbo Feng	Bicyclic heteroaryls as kinase inhibitors
EP3091021B1 (en)	2009-10-26	2019-08-28	Signal Pharmaceuticals, LLC	Methods of synthesis and purification of heteroaryl compounds
WO2011051425A1 (en)	2009-10-30	2011-05-05	Novartis Ag	N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea
KR20110049217A (ko)	2009-11-04	2011-05-12	다우어드밴스드디스플레이머티리얼 유한회사	신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자
GB0919432D0 (en)	2009-11-05	2009-12-23	Glaxosmithkline Llc	Use
NZ629615A (en)	2009-11-06	2016-01-29	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
MX2012005332A (es)	2009-11-13	2012-10-15	Oscotec Inc	Inhibidores de cinasa.
CN102740698A (zh)	2009-11-18	2012-10-17	普莱希科公司	用于激酶调节的化合物和方法及其适应症
JP2013032290A (ja)	2009-11-20	2013-02-14	Dainippon Sumitomo Pharma Co Ltd	新規縮合ピリミジン誘導体
EP2504010A4 (en)	2009-11-23	2013-04-17	Merck Sharp & Dohme	Fused Bicyclic Pyrimidine Derivatives and Methods of Use Therefor
US20130017199A1 (en)	2009-11-24	2013-01-17	AMPLIMMUNE ,Inc. a corporation	Simultaneous inhibition of pd-l1/pd-l2
EP2332939A1 (en)	2009-11-26	2011-06-15	Æterna Zentaris GmbH	Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
CA2781010A1 (en)	2009-12-01	2011-06-09	Abbott Laboratories	Novel tricyclic compounds
JP2011116840A (ja)	2009-12-02	2011-06-16	Fujifilm Corp	顔料微粒子分散体、これを用いた光硬化性組成物及びカラーフィルタ
AR079257A1 (es)	2009-12-07	2012-01-04	Novartis Ag	Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
MA33926B1 (fr)	2009-12-17	2013-01-02	Merck Sharp & Dohme	Aminopyrimidines en tant qu'inhibiteurs de la syk
EP2512476A1 (en)	2009-12-18	2012-10-24	Novartis AG	Method for treating haematological cancers
SG181917A1 (en)	2009-12-22	2012-08-30	Vertex Pharma	Isoindolinone inhibitors of phosphatidylinositol 3-kinase
FR2954317B1 (fr)	2009-12-23	2012-01-27	Galderma Res & Dev	Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
FR2954315B1 (fr)	2009-12-23	2012-02-24	Galderma Res & Dev	Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
WO2011079231A1 (en)	2009-12-23	2011-06-30	Gatekeeper Pharmaceutical, Inc.	Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
EP2519241A2 (en)	2009-12-28	2012-11-07	Afraxis, Inc.	Methods for treating autism
EP2937345B1 (en)	2009-12-29	2018-03-21	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
JP2013515785A (ja)	2009-12-29	2013-05-09	ポリエラコーポレイション	有機半導体としてのチオン酸化芳香族ビスイミドおよびそれを組み込む装置
WO2011080755A1 (en)	2009-12-29	2011-07-07	Advinus Therapeutics Private Limited	Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
KR20120124428A (ko)	2009-12-30	2012-11-13	아르퀼 인코포레이티드	치환된 피롤로-아미노피리미딘 화합물
US8329705B2 (en)	2009-12-30	2012-12-11	Arqule, Inc.	Substituted triazolo-pyrazine compounds
WO2011082266A2 (en)	2009-12-30	2011-07-07	Arqule, Inc.	Substituted heterocyclic compounds
CN102115026A (zh)	2009-12-31	2011-07-06	清华大学	一维纳米结构、其制备方法及一维纳米结构作标记的方法
US20130022629A1 (en)	2010-01-04	2013-01-24	Sharpe Arlene H	Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
WO2011082488A1 (en)	2010-01-06	2011-07-14	British Columbia Cancer Agency Branch	Bisphenol derivative therapeutics and methods for their use
KR101483215B1 (ko)	2010-01-29	2015-01-16	한미약품 주식회사	단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
WO2011094890A1 (en)	2010-02-02	2011-08-11	Argusina Inc.	Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011097717A1 (en)	2010-02-15	2011-08-18	University Of Victoria Innovation And Development Corporation	Synthesis of bicyclic compounds and method for their use as therapeutic agents
CA2789711C (en)	2010-02-17	2014-08-05	Amgen Inc.	Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
SA111320200B1 (ar)	2010-02-17	2014-02-16	ديبيوفارم اس ايه	مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
US9433621B2 (en)	2010-02-18	2016-09-06	Merck Sharp & Dohme Corp.	Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2011103460A1 (en)	2010-02-18	2011-08-25	Medivation Technologies, Inc.	Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
CN102782101B (zh)	2010-02-18	2015-10-07	Ntn株式会社	增稠剂、润滑脂及它们的制造方法以及润滑脂封入轴承
UY33227A (es)	2010-02-19	2011-09-30	Novartis Ag	Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011103557A1 (en)	2010-02-22	2011-08-25	Advanced Cancer Therapeutics, Llc	Small molecule inhibitors of pfkfb3 and glycolytic flux and their methods of use as anti-cancer therapeutics
JP5662994B2 (ja)	2010-02-26	2015-02-04	新日鉄住金化学株式会社	有機電界発光素子
WO2011109237A2 (en)	2010-03-02	2011-09-09	Emory University	Uses of noscapine and derivatives in subjects diagnosed with fap
WO2011111880A1 (ko)	2010-03-08	2011-09-15	주식회사 메디젠텍	세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2011112687A2 (en)	2010-03-10	2011-09-15	Kalypsys, Inc.	Heterocyclic inhibitors of histamine receptors for the treatment of disease
BR112012022943A2 (pt)	2010-03-11	2018-06-05	Gilead Connecticut Inc	inibidores de syk de imidazopiridnas
JP2013522292A (ja)	2010-03-16	2013-06-13	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	インダゾール化合物およびそれらの使用
WO2011119894A2 (en)	2010-03-24	2011-09-29	Kinagen, Inc	Heterocyclic compounds useful for kinase inhibition
US8791257B2 (en)	2010-03-31	2014-07-29	Bristol-Myers Squibb Company	Substituted pyrrolotriazines as protein kinase inhibitors
CN102153551B (zh)	2010-04-02	2012-04-25	济南海乐医药技术开发有限公司	基于吲唑或氮杂吲唑的双芳基脲或硫脲类结构抗肿瘤药物
JP5724204B2 (ja)	2010-04-07	2015-05-27	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置、及び照明装置
ES2562419T3 (es)	2010-04-13	2016-03-04	Rigel Pharmaceuticals, Inc.	Compuestos de 2,4-pirimidinodiamina y sus profármacos y sus usos
US8741903B2 (en)	2010-04-16	2014-06-03	Novartis Ag	Organic compound for use in the treatment of hepatocellular cancer (HCC)
US8822447B2 (en)	2010-04-22	2014-09-02	Janssen Pharmaceutica Nv	Indazole compounds useful as ketohexokinase inhibitors
AR081331A1 (es)	2010-04-23	2012-08-08	Cytokinetics Inc	Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
KR20130069640A (ko)	2010-04-23	2013-06-26	키네타, 인크.	항-바이러스 화합물
CN103025744A (zh)	2010-04-30	2013-04-03	百时美施贵宝公司	作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
GB201007286D0 (en)	2010-04-30	2010-06-16	Astex Therapeutics Ltd	New compounds
US8759398B2 (en)	2010-05-03	2014-06-24	Biolink Life Sciences, Inc.	Phosphorus binder composition for treatment of hyperphosphatemia
WO2011140338A1 (en)	2010-05-05	2011-11-10	Gatekeeper Pharmaceuticals, Inc.	Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
TWI513694B (zh)	2010-05-11	2015-12-21	Amgen Inc	抑制間變性淋巴瘤激酶的嘧啶化合物
BR112012028764A2 (pt)	2010-05-11	2017-03-14	Aveo Pharmaceuticals Inc	anticor-pos antifgfr2
WO2011141848A1 (en)	2010-05-11	2011-11-17	Pfizer Inc.	Morpholine compounds as mineralocorticoid receptor antagonists
EP2569301A1 (en)	2010-05-12	2013-03-20	Abbvie Inc.	Indazole inhibitors of kinase
EP2568989B1 (en)	2010-05-12	2021-03-24	Spectrum Pharmaceuticals, Inc.	Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
GB201008134D0 (en)	2010-05-14	2010-06-30	Medical Res Council Technology	Compounds
WO2011147199A1 (en)	2010-05-28	2011-12-01	Versitech Limited	Compounds and methods for treating viral infections
WO2011147198A1 (en)	2010-05-28	2011-12-01	Versitech Limited	Compounds and methods for treatment of proliferative diseases
WO2011153553A2 (en)	2010-06-04	2011-12-08	The Regents Of The University Of California	Methods and compositions for kinase inhibition
KR101531448B1 (ko)	2010-06-04	2015-06-24	에프. 호프만-라 로슈 아게	Lrrk2 조절제로서의 아미노피리미딘 유도체
WO2011155983A1 (en)	2010-06-07	2011-12-15	Bikam Pharmaceuticals Inc.	Opsin-binding ligands, compositions and methods of use
TW201210597A (en)	2010-06-09	2012-03-16	Gilead Sciences Inc	Inhibitors of hepatitis C virus
US8299117B2 (en)	2010-06-16	2012-10-30	Metabolex Inc.	GPR120 receptor agonists and uses thereof
US9163087B2 (en)	2010-06-18	2015-10-20	The Brigham And Women's Hospital, Inc.	Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
WO2011163330A1 (en)	2010-06-24	2011-12-29	Merck Sharp & Dohme Corp.	Novel heterocyclic compounds as erk inhibitors
US8907053B2 (en)	2010-06-25	2014-12-09	Aurigene Discovery Technologies Limited	Immunosuppression modulating compounds
KR101486782B1 (ko)	2010-06-27	2015-01-28	킹 사우드 유니버시티	무한 중첩된 해시 체인들에 의한 1회용 패스워드 인증
EP2588110B1 (en)	2010-07-02	2018-10-17	University Health Network	Methods of targeting pten mutant diseases and compositions therefor
WO2012004217A1 (en)	2010-07-06	2012-01-12	Novartis Ag	Cyclic ether compounds useful as kinase inhibitors
FR2962437B1 (fr)	2010-07-06	2012-08-17	Sanofi Aventis	Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr)	2010-07-06	2012-08-17	Sanofi Aventis	Derives d'indolizines, procedes de preparation et application en therapeutique
DE102010031127A1 (de)	2010-07-08	2012-01-12	Endress + Hauser Flowtec Ag	Messaufnehmer eines thermischen Durchflussmessgeräts zur Ermittlung des Durchflusses eines Mediums durch ein Messrohr und Verfahren zu dessen Herstellung
AU2011276955B2 (en)	2010-07-09	2014-11-06	The Walter And Eliza Hall Institute Of Medical Research	Protein kinase inhibitors and methods of treatment
WO2012009258A2 (en)	2010-07-13	2012-01-19	Edward Roberts	Peptidomimetic galanin receptor modulators
US20130210807A1 (en)	2010-07-14	2013-08-15	Nigel J Liverton	Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors.
TW201206946A (en)	2010-07-15	2012-02-16	Bristol Myers Squibb Co	Compounds for the reduction of beta-amyloid production
CN103003262A (zh)	2010-07-16	2013-03-27	协和发酵麒麟株式会社	含氮芳香族杂环衍生物
WO2012008564A1 (ja)	2010-07-16	2012-01-19	協和発酵キリン株式会社	含窒素芳香族複素環誘導体
WO2012013713A2 (en)	2010-07-28	2012-02-02	Bayer Pharma Aktiengesellschaft	Substituted imidazo[1,2-b]pyridazines
EP2413140A1 (en)	2010-07-29	2012-02-01	Sanofi	Method for identifying a compound having an antiarrhythmic effect as well as uses relating thereto
KR20120012431A (ko)	2010-07-30	2012-02-09	롬엔드하스전자재료코리아유한회사	유기발광화합물을 발광재료로서 채용하고 있는 유기 전계 발광 소자
WO2012019093A1 (en)	2010-08-05	2012-02-09	Human Biomolecular Research Institute	Synthetic compounds and methods to decrease nicotine self-administration
US8883839B2 (en)	2010-08-13	2014-11-11	Abbott Laboratories	Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en)	2010-08-13	2015-06-09	AbbVie Deutschland GmbH & Co. KG	Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012027239A1 (en)	2010-08-23	2012-03-01	Schering Corporation	NOVEL PYRAZOLO[1,5-a]PYRROLO[3,2-e]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030990A1 (en)	2010-09-01	2012-03-08	Gilead Connecticut, Inc.	Pyridazinones, method of making, and method of use thereof
CN106220614B (zh)	2010-09-01	2019-07-16	吉利德康涅狄格有限公司	吡啶酮/吡嗪酮、其制备方法及使用方法
WO2012032065A1 (en)	2010-09-08	2012-03-15	Glaxo Group Limited	Indazole derivatives for use in the treatment of influenza virus infection
AR082799A1 (es)	2010-09-08	2013-01-09	Ucb Pharma Sa	Derivados de quinolina y quinoxalina como inhibidores de quinasa
US8735390B2 (en)	2010-09-08	2014-05-27	Glaxosmithkline Intellectual Property Development Limited	Polymorphs and salts
TWI541243B (zh)	2010-09-10	2016-07-11	拜耳知識產權公司	經取代咪唑并嗒
EP2618219A4 (en)	2010-09-14	2015-03-18	Hodogaya Chemical Co Ltd	LOAD CONTROLLER AND TONER THEREOF
CN102399233B (zh)	2010-09-15	2014-08-13	山东轩竹医药科技有限公司	PI3K和mTOR双重抑制剂类化合物
CN102399220A (zh)	2010-09-15	2012-04-04	黄振华	三并环类PI3K和mTOR双重抑制剂
WO2012036233A1 (ja)	2010-09-17	2012-03-22	塩野義製薬株式会社	メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
GB201015949D0 (en)	2010-09-22	2010-11-03	Medical Res Council Technology	Compounds
JO3062B1 (ar)	2010-10-05	2017-03-15	Lilly Co Eli	R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
WO2012054364A2 (en)	2010-10-22	2012-04-26	Merck Sharp & Dohme Corp.	Bicyclic diamines as janus kinase inhibitors
HRP20161092T1 (hr)	2010-10-25	2016-10-21	G1 Therapeutics, Inc.	Cdk inhibitori
JP2012092049A (ja)	2010-10-27	2012-05-17	Sumitomo Chemical Co Ltd	有害動物防除組成物及び有害動物の防除方法
EP2632466A4 (en)	2010-10-29	2014-03-19	Univ Emory	CHINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF AND USES THEREOF
WO2012061337A1 (en)	2010-11-02	2012-05-10	Exelixis, Inc.	Fgfr2 modulators
US20120115903A1 (en)	2010-11-10	2012-05-10	Gruenenthal Gmbh	Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands
CA2815179A1 (en)	2010-11-10	2012-05-18	Actelion Pharmaceuticals Ltd	Lactam derivatives useful as orexin receptor antagonists
JP2012116825A (ja)	2010-11-11	2012-06-21	Ehime Univ	アセンジイミド化合物の製造方法
KR101171232B1 (ko)	2010-11-15	2012-08-06	단국대학교 산학협력단	스파이로 화합물 및 이를 포함하는 유기전계 발광소자
WO2012065297A1 (en)	2010-11-16	2012-05-24	Impact Therapeutics, Inc.	3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
WO2012068343A1 (en)	2010-11-17	2012-05-24	Amgen Inc.	Quinoline derivatives as pik3 inhibitors
JP5898687B2 (ja)	2010-11-18	2016-04-06	カシナライライノバファーマシューティカルズプライベートリミテッド	置換４−（セレノフェン−２（または３）−イルアミノ）ピリミジン化合物およびその使用方法
GB201020179D0 (en)	2010-11-29	2011-01-12	Astex Therapeutics Ltd	New compounds
US9090593B2 (en)	2010-12-09	2015-07-28	Amgen Inc.	Bicyclic compounds as Pim inhibitors
EP2651404B1 (en)	2010-12-14	2015-10-14	Electrophoretics Limited	Casein kinase 1delta (ck1delta) inhibitors
LT2655357T (lt)	2010-12-20	2016-10-10	Merck Serono S.A.	Indazolilo triazolo dariniai, kaip irak inhibitoriai
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
AU2011348638B2 (en)	2010-12-22	2015-05-21	Leo Laboratories Limited	3-acyl-ingenols II
CN102603628B (zh)	2010-12-22	2016-08-17	香港理工大学	作为抗癌试剂的喹啉衍生物
NZ710133A (en)	2010-12-22	2016-08-26	Leo Lab Ltd	Ingenol-3-acylates iii and ingenol-3-carbamates
EP2468258A1 (en)	2010-12-22	2012-06-27	LEK Pharmaceuticals d.d.	Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
MX2013007261A (es)	2010-12-23	2013-11-04	Amgen Inc	Compuestos heterociclicos y sus usos.
JP5691508B2 (ja)	2010-12-27	2015-04-01	Jnc株式会社	ジイミド化合物ならびにインクジェット用インクおよびその用途
KR101466150B1 (ko)	2010-12-31	2014-11-27	제일모직 주식회사	유기광전소자용 화합물 및 이를 포함하는 유기광전소자
JP5860818B2 (ja)	2011-01-06	2016-02-16	Ｊｘ日鉱日石エネルギー株式会社	イミド化合物及びその製造方法、グリース用増ちょう剤並びにグリース組成物
US8362023B2 (en)	2011-01-19	2013-01-29	Hoffmann-La Roche Inc.	Pyrazolo pyrimidines
FR2970967B1 (fr)	2011-01-27	2013-02-15	Pf Medicament	Derives de type azaindazole ou diazaindazole comme medicament
EP2487159A1 (en)	2011-02-11	2012-08-15	MSD Oss B.V.	RorgammaT inhibitors
US20140303144A1 (en)	2011-02-18	2014-10-09	Medivation Technologies, Inc.	Compounds and methods of treating hypertension
WO2012116237A2 (en)	2011-02-23	2012-08-30	Intellikine, Llc	Heterocyclic compounds and uses thereof
TWI532742B (zh)	2011-02-28	2016-05-11	艾伯維有限公司	激酶之三環抑制劑
CA2829988A1 (en)	2011-03-17	2012-09-20	Novartis Ag	Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
MY161199A (en)	2011-03-23	2017-04-14	Amgen Inc	Fused tricyclic dual inhibitors of cdk 4/6 and flt3
ITPD20110091A1 (it)	2011-03-24	2012-09-25	Univ Padova	Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico.
CA2831146C (en)	2011-03-25	2019-06-04	Abbvie Inc.	Trpv1 antagonists
CA2828890A1 (en)	2011-04-07	2012-10-11	Genentech, Inc.	Anti-fgfr4 antibodies and methods of use
FR2974088A1 (fr)	2011-04-12	2012-10-19	Pf Medicament	Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
MY175338A (en)	2011-05-16	2020-06-19	Genentech Inc	Fgfr1 agonists and methods of use
CA2836203A1 (en)	2011-05-17	2012-11-22	Bayer Intellectual Property Gmbh	Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
WO2012158795A1 (en)	2011-05-17	2012-11-22	Principia Biopharma Inc.	Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
EP2709729A1 (en)	2011-05-19	2014-03-26	Novartis AG	4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl]- 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma
US9730929B2 (en)	2011-06-01	2017-08-15	Bayer Intellectual Property Gmbh	Substituted aminoimidazopyridazines
TW201316991A (zh)	2011-06-03	2013-05-01	Millennium Pharm Inc	Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合
KR101417285B1 (ko)	2011-06-13	2014-07-09	주식회사 엘지화학	신규한 화합물 및 이를 이용한 유기 전자 소자
US9284319B2 (en)	2011-06-22	2016-03-15	Bayer Intellectual Property Gmbh	Heterocyclyl aminoimidazopyridazines
US8846656B2 (en)	2011-07-22	2014-09-30	Novartis Ag	Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
MX355852B (es)	2011-08-12	2018-05-02	Hoffmann La Roche	Compuestos de pirazolo [3,4-c] piridina y métodos de uso.
CA2841458C (en)	2011-08-12	2019-07-16	Nissan Chemical Industries, Ltd.	Tricyclic heterocyclic compounds and jak inhibitors
JP2013049251A (ja)	2011-08-31	2013-03-14	Fujifilm Corp	レーザー彫刻用レリーフ印刷版原版、並びに、レリーフ印刷版及びその製版方法
WO2013033981A1 (zh)	2011-09-06	2013-03-14	江苏先声药物研究有限公司	一类2,7-萘啶衍生物及其制备方法和应用
WO2013039854A1 (en)	2011-09-15	2013-03-21	Merck Sharp & Dohme Corp.	Compositions and methods for treating cancer
US9376435B2 (en)	2011-09-23	2016-06-28	Jawaharlal Nehru Centre For Advanced Scientific Research	Chromophores for the detection of volatile organic compounds
US9320737B2 (en)	2011-09-23	2016-04-26	Bayer Intellectual Property Gmbh	Substituted imidazopyridazines
US20140227321A1 (en)	2011-09-30	2014-08-14	Kineta, Inc.	Anti-viral compounds
UA111382C2 (uk)	2011-10-10	2016-04-25	Оріон Корпорейшн	Інгібітори протеїнкінази
US9580390B2 (en)	2011-10-12	2017-02-28	University Health Network	Indazole compounds as kinase inhibitors and method of treating cancer with same
KR101897044B1 (ko)	2011-10-20	2018-10-23	에스에프씨 주식회사	유기금속 화합물 및 이를 포함하는 유기전계발광소자
WO2013063003A1 (en)	2011-10-28	2013-05-02	Novartis Ag	Method of treating gastrointestinal stromal tumors
BR112014009993A2 (pt)	2011-10-28	2017-04-25	Novartis Ag	método para o tratamento de tumores do estroma gastrointestinal
WO2013088191A1 (en)	2011-12-12	2013-06-20	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
EP3282004B2 (en)	2011-12-13	2025-03-26	Ecolab USA Inc.	Warewashing method
FR2985258A1 (fr)	2011-12-28	2013-07-05	Sanofi Sa	Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
FR2985257B1 (fr)	2011-12-28	2014-02-14	Sanofi Sa	Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
US10026905B2 (en)	2012-01-18	2018-07-17	Duk San Neolux Co., Ltd.	Compound, organic electric element using the same, and an electronic device thereof
WO2013109027A1 (ko)	2012-01-18	2013-07-25	덕산하이메탈(주)	화합물, 이를 이용한 유기전기소자 및 그 전자 장치
PL2657233T3 (pl)	2012-01-19	2015-01-30	Taiho Pharmaceutical Co Ltd	3,5-dipodstawiony związek alkinylobenzenowy i jego sól
ES2581065T3 (es)	2012-02-23	2016-08-31	Bayer Intellectual Property Gmbh	Benzotienil-pirrolotriazinas sustituidas y usos de las mismas
JP2013179181A (ja)	2012-02-28	2013-09-09	Sumitomo Chemical Co Ltd	有機光電変換素子
NZ629442A (en)	2012-03-14	2016-12-23	Lupin Ltd	Heterocyclyl compounds as mek inhibitors
CN104321058A (zh)	2012-03-30	2015-01-28	诺华股份有限公司	用于治疗低磷血性疾病的fgfr抑制剂
JP5120580B1 (ja)	2012-05-14	2013-01-16	Ｊｓｒ株式会社	液晶配向剤
CA2874208C (en)	2012-05-20	2020-05-12	Mitralheal Ltd.	Prosthetic mitral valve
DK2861595T5 (en)	2012-06-13	2018-01-15	Incyte Holdings Corp	Substituted tricyclic compounds as FGFR inhibitors
BR112015000349A2 (pt)	2012-07-11	2017-06-27	Novartis Ag	método de tratamento de tumores estromais gastrointestinais
RU2679130C2 (ru)	2012-07-11	2019-02-06	Блюпринт Медсинс Корпорейшн	Ингибиторы рецептора фактора роста фибробластов
WO2014019186A1 (en)	2012-08-02	2014-02-06	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
EP2880028B1 (en)	2012-08-02	2020-09-30	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
KR101985259B1 (ko)	2012-08-10	2019-06-03	제이에스알 가부시끼가이샤	액정 배향제 및 화합물
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
WO2014044846A1 (en)	2012-09-24	2014-03-27	Evotec (Uk) Ltd.	3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en)	2012-09-26	2014-04-03	Evotec (Uk) Ltd.	Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
WO2014062454A1 (en)	2012-10-15	2014-04-24	Merck Sharp & Dohme Corp.	Compositions and methods for treating cancer
KR102000211B1 (ko)	2012-10-29	2019-09-30	삼성디스플레이 주식회사	유기금속 화합물 및 이를 포함한 유기 발광 소자
ES2651347T3 (es)	2012-11-28	2018-01-25	Merck Sharp & Dohme Corp.	Composiciones y métodos para el tratamiento del cáncer
US20140148548A1 (en)	2012-11-28	2014-05-29	Central Glass Company, Limited	Fluorine-Containing Polymerizable Monomer And Polymer Compound Using Same
WO2014089913A1 (zh)	2012-12-12	2014-06-19	山东亨利医药科技有限责任公司	作为酪氨酸激酶抑制剂的并环化合物
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
TWI629266B (zh)	2012-12-28	2018-07-11	藍印藥品公司	纖維母細胞生長因子受體之抑制劑
WO2014105849A1 (en)	2012-12-28	2014-07-03	Xoma (Us) Llc	Antibodies specific for fgfr4 and methods of use
KR102030587B1 (ko)	2013-01-09	2019-10-10	에스에프씨주식회사	두 개의 나프틸기를 포함하는 비대칭 안트라센 유도체 및 이를 포함하는 유기 발광 소자
US9695178B2 (en)	2013-01-15	2017-07-04	Suzhou Kintor Pharmaceuticals, Inc.	6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof
CN103694236B (zh)	2013-01-15	2017-05-31	苏州开拓药业股份有限公司	一种嘧啶骨架具有刺猬通路拮抗剂活性的抗肿瘤化合物
KR101456626B1 (ko)	2013-02-01	2014-11-03	대영이앤비 주식회사	냉장고 부압 방지 장치
WO2014136972A1 (ja)	2013-03-07	2014-09-12	国立大学法人九州大学	超分子複合体、発光体、および有機化合物検出用のセンサー素子
WO2014138485A1 (en)	2013-03-08	2014-09-12	Irm Llc	Ex vivo production of platelets from hematopoietic stem cells and the product thereof
US9771327B2 (en)	2013-03-13	2017-09-26	Flatley Discovery Lab, Llc	Compounds and methods for the treatment of cystic fibrosis
US9498532B2 (en)	2013-03-13	2016-11-22	Novartis Ag	Antibody drug conjugates
EP2970258B1 (en)	2013-03-14	2018-04-18	AbbVie Deutschland GmbH & Co KG	Novel inhibitor compounds of phosphodiesterase type 10a
EP3943087A1 (en)	2013-03-15	2022-01-26	Celgene CAR LLC	Heteroaryl compounds and uses thereof
EP2970231A1 (en)	2013-03-15	2016-01-20	Blueprint Medicines Corporation	Piperazine derivatives and their use as kit modulators
MX374558B (es)	2013-03-15	2025-03-06	Sanofi Sa	Compuestos de heteroarilo y sus usos.
US9321786B2 (en)	2013-03-15	2016-04-26	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
TWI628176B (zh)	2013-04-04	2018-07-01	奧利安公司	蛋白質激酶抑制劑
KR101573611B1 (ko)	2013-04-17	2015-12-01	주식회사 엘지화학	플러렌 유도체, 이를 이용한 유기 태양 전지 및 이의 제조 방법
MY181497A (en)	2013-04-19	2020-12-23	Incyte Holdings Corp	Bicyclic heterocycles as fgfr inhibitors
BR112015026143A2 (pt)	2013-04-19	2017-10-17	Covagen Ag	moléculas ligante biespecífica e de ácido nucleico, vetor, célula hospedeira ou hospedeiro não humano, e, composição farmacêutica
GB201307577D0 (en)	2013-04-26	2013-06-12	Astex Therapeutics Ltd	New compounds
WO2014182829A1 (en)	2013-05-09	2014-11-13	Principia Biopharma Inc.	Quinolone derivatives as fibroblast growth factor inhibitors
AU2014280046B2 (en)	2013-06-14	2019-07-11	Sanofi	Pyrazolopyridine derivatives for use in the treatment of bladder cancer
JP6380862B2 (ja)	2013-06-28	2018-08-29	ベイジーンリミテッド	複数種類のキナーゼの阻害剤としての縮合三環式アミド系化合物
DK3013798T3 (en)	2013-06-28	2018-10-15	Beigene Ltd	Condensed tricyclic urea compounds such as RAF kinase and / or RAF kinase dimer inhibitors
JP6677637B2 (ja)	2013-07-02	2020-04-08	シンジェンタパーティシペーションズアーゲー	有害生物防除的に活性な、硫黄含有置換基を有する二環式または三環式複素環
CA2917667A1 (en)	2013-07-09	2015-01-15	Dana-Farber Cancer Institute, Inc.	Kinase inhibitors for the treatment of disease
JP6018547B2 (ja)	2013-07-09	2016-11-02	大成ロテック株式会社	舗装機械
AU2014287016B2 (en)	2013-07-11	2018-11-01	Acea Biosciences Inc.	Pyrimidine derivatives as kinase inhibitors
TW201605452A (zh)	2013-08-28	2016-02-16	安斯泰來製藥股份有限公司	以嘧啶化合物作爲有效成分之醫藥組成物
PE20160679A1 (es)	2013-10-18	2016-08-04	Eisai Randd Man Co Ltd	Inhibidores de pirimidina del fgfr4
KR102405452B1 (ko)	2013-10-25	2022-06-03	블루프린트 메디신즈 코포레이션	섬유아세포 성장 인자 수용체의 억제
EA028819B1 (ru)	2013-10-25	2018-01-31	Новартис Аг	Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
FR3012330B1 (fr)	2013-10-29	2015-10-23	Oreal	Composition biphase comprenant un ester d'acide gras et de sucre ou un alkylpolyglucoside liquide, de hlb < 8, et un alcane ramifie en c8-c18
WO2015066452A2 (en)	2013-11-01	2015-05-07	Foundation Medicine, Inc.	Methods of treating pediatric cancers
US9695165B2 (en)	2014-01-15	2017-07-04	Blueprint Medicines Corporation	Inhibitors of the fibroblast growth factor receptor
EP3184521B1 (en)	2014-08-19	2021-10-06	Shanghai Haihe Pharmaceutical Co., Ltd.	Indazole compounds as fgfr kinase inhibitors, preparation and use thereof
CN104262330B (zh)	2014-08-27	2016-09-14	广东东阳光药业有限公司	一种脲取代联苯类化合物及其组合物及用途
US10350206B2 (en)	2014-09-19	2019-07-16	Bayer Pharma Aktiengesellschaft	Benzyl substituted indazoles as BUB1 inhibitors
US20160115164A1 (en)	2014-10-22	2016-04-28	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
SG11201706729SA (en)	2015-02-20	2017-09-28	Univ Oregon Health & Science	Derivatives of sobetirome
AU2016219822B2 (en)	2015-02-20	2020-07-09	Incyte Holdings Corporation	Bicyclic heterocycles as FGFR inhibitors
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016192680A1 (en)	2015-06-03	2016-12-08	Triastek, Inc.	Dosage forms and use thereof
KR102513978B1 (ko)	2015-07-15	2023-03-27	프로타고니스트 테라퓨틱스, 인코포레이티드	인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 그의 용도
UA120463C2 (uk)	2015-07-15	2019-12-10	Ф. Хоффманн-Ля Рош Аг	Похідні етинілу як модулятори метаботропного рецептора глутамату
GB201512369D0 (en)	2015-07-15	2015-08-19	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
AU2016294426B2 (en)	2015-07-15	2018-10-18	Cabot Corporation	Methods of making an elastomer composite reinforced with silica and carbon black and products containing same
PE20181151A1 (es)	2015-07-30	2018-07-17	Macrogenics Inc	Moleculas de union a pd-1 y metodos de uso de las mismas
WO2017023989A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023988A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024015A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023972A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024003A1 (en)	2015-08-03	2017-02-09	Samumed, Llc	3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206909B2 (en)	2015-08-03	2019-02-19	Samumed, Llc	3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10519169B2 (en)	2015-08-03	2019-12-31	Samumed, Llc	3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
AU2015406253B2 (en)	2015-08-20	2021-02-25	Js Innopharm (Shanghai) Ltd.	Pyrazolo fused heterocyclic compounds as ERK inhibitors
US10975071B2 (en)	2015-09-28	2021-04-13	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
US20170107216A1 (en)	2015-10-19	2017-04-20	Incyte Corporation	Heterocyclic compounds as immunomodulators
AU2016341445B2 (en)	2015-10-23	2020-08-27	Array Biopharma, Inc.	2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
JP7148401B2 (ja)	2015-11-19	2022-10-05	インサイト・コーポレイション	免疫調節剤としての複素環化合物
ES2916874T3 (es)	2015-12-17	2022-07-06	Incyte Corp	Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
PL3394033T3 (pl)	2015-12-22	2021-05-31	Incyte Corporation	Związki heterocykliczne jako immunomodulatory
MA44860A (fr)	2016-05-06	2019-03-13	Incyte Holdings Corp	Composés hétérocycliques utilisés comme immunomodulateurs
US20170342060A1 (en)	2016-05-26	2017-11-30	Incyte Corporation	Heterocyclic compounds as immunomodulators
HRP20221030T1 (hr)	2016-06-20	2022-11-11	Incyte Corporation	Heterociklički spojevi kao imunomodulatori
WO2017223414A1 (en)	2016-06-24	2017-12-28	Incyte Corporation	HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US20180016260A1 (en)	2016-07-14	2018-01-18	Incyte Corporation	Heterocyclic compounds as immunomodulators
WO2018044783A1 (en)	2016-08-29	2018-03-08	Incyte Corporation	Heterocyclic compounds as immunomodulators
WO2018041091A1 (en)	2016-08-30	2018-03-08	Sunshine Lake Pharma Co., Ltd.	Inhibitors of influenza virus replication, application methods and uses thereof
WO2018049214A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
BR112019005305A2 (pt)	2016-10-05	2019-07-02	Zeno Royalties & Milestones Llc	compostos espirocíclicos
KR101755556B1 (ko)	2016-11-18	2017-07-07	주식회사 케마스	육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101834366B1 (ko)	2016-11-21	2018-03-05	주식회사 케마스	육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101844049B1 (ko)	2016-12-05	2018-03-30	주식회사 케마스	육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물
KR101844050B1 (ko)	2016-12-09	2018-05-14	주식회사 케마스	육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
ES2918974T3 (es)	2016-12-22	2022-07-21	Incyte Corp	Compuestos heteroaromaticos biciclicos como inmunomoduladores
US20180177784A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Heterocyclic compounds as immunomodulators
US20180179179A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Heterocyclic compounds as immunomodulators
EP3558989B1 (en)	2016-12-22	2021-04-14	Incyte Corporation	Triazolo[1,5-a]pyridine derivatives as immunomodulators
US10806785B2 (en)	2016-12-22	2020-10-20	Incyte Corporation	Immunomodulator compounds and methods of use
IL295660A (en)	2016-12-22	2022-10-01	Incyte Corp	Benzooxazole derivatives as immunomodulators
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018234354A1 (en)	2017-06-20	2018-12-27	Grünenthal GmbH	NOVEL SUBSTITUTED 3-INDOLE AND 3-INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
WO2019037640A1 (en)	2017-08-22	2019-02-28	Js Innopharm (Shanghai) Ltd	HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USING THE SAME
CA3079607A1 (en)	2017-10-19	2019-04-25	Effector Therapeutics, Inc.	Benzimidazole-indole inhibitors of mnk1 and mnk2
US11339166B2 (en)	2017-12-02	2022-05-24	Galapagos Nv	Compounds and pharmaceutical compositions thereof for the treatment of diseases
FI3774791T3 (fi)	2018-03-30	2023-03-21	Incyte Corp	Heterosyklisiä yhdisteitä immunomodulaattoreina
JP2021523121A (ja)	2018-05-04	2021-09-02	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	Ｆｇｆｒ阻害剤の固体形態及びその調製プロセス
MA52493A (fr)	2018-05-04	2021-03-10	Incyte Corp	Sels d'un inhibiteur de fgfr
EP4520328A3 (en)	2018-05-11	2025-04-16	Incyte Corporation	Heterocyclic compounds as immunomodulators
EP3836923B1 (en)	2018-08-14	2024-10-16	OssiFi Therapeutics LLC	Pyrrolo - dipyridine compounds for the treatment of bone loss
EP3846904B1 (en)	2018-09-07	2023-05-31	Merck Patent GmbH	5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives
WO2020081898A1 (en)	2018-10-20	2020-04-23	The Johns Hopkins University	Non-invasive urinary biomarkers for the detection of urothelial carcinoma of the bladder
CN113474337A (zh)	2018-12-19	2021-10-01	奥瑞生物药品公司	作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
EP3898626A1 (en)	2018-12-19	2021-10-27	Array Biopharma, Inc.	Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
AU2020366006A1 (en)	2019-10-14	2022-04-21	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CN115151539A (zh)	2019-12-04	2022-10-04	因赛特公司	Fgfr抑制剂的衍生物
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US12065494B2 (en)	2021-04-12	2024-08-20	Incyte Corporation	Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent

2013
- 2013-06-12 DK DK13783125.1T patent/DK2861595T5/en active
- 2013-06-12 PH PH1/2019/502809A patent/PH12019502809B1/en unknown
- 2013-06-12 HR HRP20170430TT patent/HRP20170430T1/hr unknown
- 2013-06-12 SM SM20170146T patent/SMT201700146T1/it unknown
- 2013-06-12 MX MX2014015192A patent/MX359293B/es active IP Right Grant
- 2013-06-12 SG SG11201408238WA patent/SG11201408238WA/en unknown
- 2013-06-12 BR BR112014030812-8A patent/BR112014030812B1/pt active IP Right Grant
- 2013-06-12 CN CN201710874686.0A patent/CN107652289B/zh active Active
- 2013-06-12 PE PE2019000866A patent/PE20190736A1/es unknown
- 2013-06-12 ES ES18198112T patent/ES2832497T3/es active Active
- 2013-06-12 PT PT16203866T patent/PT3176170T/pt unknown
- 2013-06-12 CN CN201710395346.XA patent/CN107383009B/zh active Active
- 2013-06-12 EP EP20192679.7A patent/EP3822273B1/en active Active
- 2013-06-12 PL PL18198112T patent/PL3495367T3/pl unknown
- 2013-06-12 WO PCT/US2013/045309 patent/WO2014007951A2/en active Application Filing
- 2013-06-12 SI SI201331298T patent/SI3176170T1/sl unknown
- 2013-06-12 RS RS20190048A patent/RS58514B1/sr unknown
- 2013-06-12 ME MEP-2019-2A patent/ME03300B/me unknown
- 2013-06-12 NZ NZ702747A patent/NZ702747A/en unknown
- 2013-06-12 HU HUE16203866A patent/HUE042374T2/hu unknown
- 2013-06-12 EP EP16203866.5A patent/EP3176170B1/en active Active
- 2013-06-12 KR KR1020207021884A patent/KR102406771B1/ko active Active
- 2013-06-12 CA CA2876689A patent/CA2876689C/en active Active
- 2013-06-12 IL IL289834A patent/IL289834B2/en unknown
- 2013-06-12 ES ES20192679T patent/ES2984771T3/es active Active
- 2013-06-12 CA CA3149881A patent/CA3149881A1/en active Pending
- 2013-06-12 DK DK18198112.7T patent/DK3495367T3/da active
- 2013-06-12 EP EP24164194.3A patent/EP4403216A3/en active Pending
- 2013-06-12 UA UAA201801562A patent/UA125503C2/uk unknown
- 2013-06-12 SG SG10201610416TA patent/SG10201610416TA/en unknown
- 2013-06-12 ES ES13783125T patent/ES2618003T3/es active Active
- 2013-06-12 RS RS20170276A patent/RS55908B1/sr unknown
- 2013-06-12 MX MX2018006473A patent/MX389376B/es unknown
- 2013-06-12 UA UAA201500191A patent/UA117347C2/uk unknown
- 2013-06-12 AR ARP130102068A patent/AR091424A1/es active IP Right Grant
- 2013-06-12 KR KR1020227018808A patent/KR102556118B1/ko active Active
- 2013-06-12 SM SM20200673T patent/SMT202000673T1/it unknown
- 2013-06-12 PL PL13783125T patent/PL2861595T3/pl unknown
- 2013-06-12 EP EP13783125.1A patent/EP2861595B9/en active Active
- 2013-06-12 KR KR1020157000701A patent/KR102140426B1/ko active Active
- 2013-06-12 EA EA201590005A patent/EA036592B1/ru unknown
- 2013-06-12 SI SI201330583A patent/SI2861595T1/sl unknown
- 2013-06-12 MY MYPI2014003396A patent/MY171375A/en unknown
- 2013-06-12 ME MEP-2017-67A patent/ME02651B/me unknown
- 2013-06-12 NZ NZ730134A patent/NZ730134A/en unknown
- 2013-06-12 DK DK16203866.5T patent/DK3176170T3/en active
- 2013-06-12 HU HUE13783125A patent/HUE031916T2/en unknown
- 2013-06-12 AU AU2013287176A patent/AU2013287176C1/en active Active
- 2013-06-12 PL PL16203866T patent/PL3176170T3/pl unknown
- 2013-06-12 RS RS20201398A patent/RS61089B1/sr unknown
- 2013-06-12 US US13/915,775 patent/US9611267B2/en active Active
- 2013-06-12 SM SM20190040T patent/SMT201900040T1/it unknown
- 2013-06-12 LT LTEP16203866.5T patent/LT3176170T/lt unknown
- 2013-06-12 PT PT137831251T patent/PT2861595T/pt unknown
- 2013-06-12 SI SI201331805T patent/SI3495367T1/sl unknown
- 2013-06-12 PE PE2014002433A patent/PE20150684A1/es active IP Right Grant
- 2013-06-12 EP EP18198112.7A patent/EP3495367B1/en active Active
- 2013-06-12 ES ES16203866T patent/ES2704744T3/es active Active
- 2013-06-12 LT LTEP18198112.7T patent/LT3495367T/lt unknown
- 2013-06-12 CN CN201380041027.9A patent/CN104507943B/zh active Active
- 2013-06-12 HU HUE18198112A patent/HUE052195T2/hu unknown
- 2013-06-12 PT PT181981127T patent/PT3495367T/pt unknown
- 2013-06-12 LT LTEP13783125.1T patent/LT2861595T/lt unknown
- 2013-06-12 JP JP2015517376A patent/JP6301321B2/ja active Active
- 2013-06-12 NZ NZ743274A patent/NZ743274A/en unknown
- 2013-06-13 TW TW111107608A patent/TWI801156B/zh active
- 2013-06-13 TW TW102120946A patent/TWI706953B/zh active
- 2013-06-13 TW TW109132389A patent/TWI769529B/zh active
2014
- 2014-12-04 IL IL236078A patent/IL236078B/en active IP Right Grant
- 2014-12-05 MY MYPI2018000373A patent/MY188363A/en unknown
- 2014-12-10 MX MX2022000517A patent/MX2022000517A/es unknown
- 2014-12-10 PH PH12014502772A patent/PH12014502772B1/en unknown
- 2014-12-10 CL CL2014003355A patent/CL2014003355A1/es unknown
- 2014-12-16 CO CO14275934A patent/CO7240375A2/es unknown
2017
- 2017-01-18 US US15/408,768 patent/US10131667B2/en active Active
- 2017-03-16 CY CY20171100335T patent/CY1118744T1/el unknown
- 2017-08-03 CL CL2017001984A patent/CL2017001984A1/es unknown
- 2017-08-21 JP JP2017158805A patent/JP6336665B2/ja active Active
2018
- 2018-01-17 IL IL256976A patent/IL256976B/en active IP Right Grant
- 2018-05-02 JP JP2018088682A patent/JP6545863B2/ja active Active
- 2018-10-05 US US16/152,827 patent/US20190127376A1/en not_active Abandoned
2019
- 2019-01-02 HR HRP20190007TT patent/HRP20190007T1/hr unknown
- 2019-01-07 AU AU2019200066A patent/AU2019200066B2/en active Active
- 2019-02-06 CY CY20191100164T patent/CY1121299T1/el unknown
- 2019-06-19 JP JP2019113954A patent/JP6711946B2/ja active Active
2020
- 2020-04-07 US US16/842,558 patent/US11053246B2/en active Active
- 2020-05-28 JP JP2020093529A patent/JP7200170B2/ja active Active
- 2020-08-02 IL IL276433A patent/IL276433B/en active IP Right Grant
- 2020-11-18 AU AU2020270520A patent/AU2020270520B2/en active Active
- 2020-12-08 HR HRP20201966TT patent/HRP20201966T1/hr unknown
- 2020-12-14 CY CY20201101183T patent/CY1123631T1/el unknown
2021
- 2021-04-25 IL IL282622A patent/IL282622B/en unknown
- 2021-06-02 US US17/337,027 patent/US11840534B2/en active Active
- 2021-09-09 NO NO2021034C patent/NO2021034I1/no unknown
- 2021-09-09 HU HUS2100035C patent/HUS2100035I1/hu unknown
- 2021-09-10 LT LTPA2021519C patent/LTC2861595I2/lt unknown
- 2021-09-10 LU LU00222C patent/LUC00222I2/en unknown
- 2021-09-10 CY CY2021026C patent/CY2021026I1/el unknown
- 2021-09-21 NL NL301131C patent/NL301131I2/nl unknown
2022
- 2022-12-01 EC ECSENADI202291792A patent/ECSP22091792A/es unknown
- 2022-12-21 AU AU2022291504A patent/AU2022291504B2/en active Active
- 2022-12-21 JP JP2022204466A patent/JP7392096B2/ja active Active
2023
- 2023-10-20 US US18/382,210 patent/US20240246974A1/en active Pending
- 2023-11-22 JP JP2023197898A patent/JP7646791B2/ja active Active
2024
- 2024-10-30 AU AU2024227763A patent/AU2024227763A1/en active Pending
2025
- 2025-03-05 JP JP2025034502A patent/JP2025084979A/ja active Pending

Also Published As

Publication number	Publication date
CY2021026I2 (el)	2021-12-31
HRP20201966T1 (hr)	2021-02-05
CN107652289A (zh)	2018-02-02
EP3822273A1 (en)	2021-05-19
EP3176170A1 (en)	2017-06-07
CL2017001984A1 (es)	2018-03-23
MX2022000517A (es)	2022-05-18
PT3176170T (pt)	2019-02-05
TW201402574A (zh)	2014-01-16
JP7392096B2 (ja)	2023-12-05
AR091424A1 (es)	2015-02-04
DK3176170T3 (en)	2019-01-28
WO2014007951A3 (en)	2014-03-06
JP2023027344A (ja)	2023-03-01
TWI769529B (zh)	2022-07-01
PE20190736A1 (es)	2019-05-23
JP6545863B2 (ja)	2019-07-17
PH12019502809B1 (en)	2024-04-24
CN107383009A (zh)	2017-11-24
IL236078B (en)	2019-08-29
LT3495367T (lt)	2021-02-25
IL289834B2 (en)	2024-07-01
EP2861595B9 (en)	2017-06-21
MY171375A (en)	2019-10-10
US11053246B2 (en)	2021-07-06
US10131667B2 (en)	2018-11-20
SMT202000673T1 (it)	2021-01-05
SI3495367T1 (sl)	2021-01-29
JP2015521600A (ja)	2015-07-30
DK2861595T3 (en)	2017-02-13
JP6711946B2 (ja)	2020-06-17
CA2876689C (en)	2022-04-26
EP4403216A3 (en)	2024-10-16
AU2024227763A1 (en)	2025-01-02
PE20150684A1 (es)	2015-05-11
PH12014502772A1 (en)	2015-02-02
DK3495367T3 (da)	2020-11-16
JP6336665B2 (ja)	2018-06-06
CY1123631T1 (el)	2022-03-24
MX2014015192A (es)	2015-08-07
PH12014502772B1 (en)	2015-02-02
IL282622A (en)	2021-06-30
ES2618003T9 (es)	2018-03-02
PT3495367T (pt)	2020-11-12
US20200377504A1 (en)	2020-12-03
MX359293B (es)	2018-09-24
EP2861595B1 (en)	2016-12-21
CA2876689A1 (en)	2014-01-09
JP7646791B2 (ja)	2025-03-17
MY188363A (en)	2021-12-04
HUS2100035I1 (hu)	2021-10-28
TWI706953B (zh)	2020-10-11
TW202124382A (zh)	2021-07-01
ME03300B (me)	2019-07-20
EP3495367B1 (en)	2020-09-30
EA036592B1 (ru)	2020-11-26
LT3176170T (lt)	2019-04-25
AU2019200066A1 (en)	2019-01-24
CN107652289B (zh)	2020-07-21
CL2014003355A1 (es)	2015-06-12
HRP20190007T1 (hr)	2019-04-05
BR112014030812B1 (pt)	2022-11-08
NZ730134A (en)	2018-07-27
JP2025084979A (ja)	2025-06-03
JP2020143142A (ja)	2020-09-10
IL276433B (en)	2021-05-31
RS58514B1 (sr)	2019-04-30
AU2020270520B2 (en)	2023-01-05
AU2013287176C1 (en)	2023-01-19
MX389376B (es)	2025-03-20
HUE031916T2 (en)	2017-08-28
HRP20170430T1 (hr)	2017-06-16
LT2861595T (lt)	2017-02-27
SG10201610416TA (en)	2017-01-27
NO2021034I1 (no)	2021-09-09
US20130338134A1 (en)	2013-12-19
EP4403216A2 (en)	2024-07-24
KR20220080213A (ko)	2022-06-14
KR102140426B1 (ko)	2020-08-04
JP6301321B2 (ja)	2018-03-28
ES2832497T3 (es)	2021-06-10
BR112014030812A2 (pt)	2017-07-25
ECSP22091792A (es)	2023-01-31
DK2861595T5 (en)	2018-01-15
CN107383009B (zh)	2020-06-09
KR102406771B1 (ko)	2022-06-13
JP2017222709A (ja)	2017-12-21
KR20200093696A (ko)	2020-08-05
ES2618003T8 (es)	2021-08-24
HUE042374T2 (hu)	2019-06-28
US11840534B2 (en)	2023-12-12
HK1212326A1 (en)	2016-06-10
ES2704744T3 (es)	2019-03-19
CN104507943B (zh)	2017-11-21
US20190127376A1 (en)	2019-05-02
LUC00222I2 (es)	2024-10-04
PL3176170T3 (pl)	2019-05-31
UA117347C2 (uk)	2018-07-25
TWI801156B (zh)	2023-05-01
US20240246974A1 (en)	2024-07-25
SMT201900040T1 (it)	2019-05-10
CY1121299T1 (el)	2020-05-29
RS61089B1 (sr)	2020-12-31
HUE052195T2 (hu)	2021-04-28
JP2019178156A (ja)	2019-10-17
AU2022291504A1 (en)	2023-02-02
EP3822273B1 (en)	2024-04-10
EA201590005A1 (ru)	2015-05-29
SI3176170T1 (sl)	2019-05-31
CO7240375A2 (es)	2015-04-17
WO2014007951A2 (en)	2014-01-09
US20210380587A1 (en)	2021-12-09
CA3149881A1 (en)	2014-01-09
LTPA2021519I1 (es)	2021-09-27
KR102556118B1 (ko)	2023-07-19
JP7200170B2 (ja)	2023-01-06
EP3176170B1 (en)	2018-11-14
EP2861595A2 (en)	2015-04-22
PL3495367T3 (pl)	2021-04-19
IL276433A (en)	2020-09-30
ES2984771T3 (es)	2024-10-31
JP2018135377A (ja)	2018-08-30
NZ743274A (en)	2019-07-26
IL256976B (en)	2020-08-31
KR20150036044A (ko)	2015-04-07
CY1118744T1 (el)	2017-07-12
AU2022291504B2 (en)	2024-08-01
EP3495367A1 (en)	2019-06-12
AU2013287176A1 (en)	2015-01-15
UA125503C2 (uk)	2022-04-13
CY2021026I1 (el)	2021-12-31
ES2618003T3 (es)	2017-06-20
AU2020270520A1 (en)	2020-12-17
US20170137424A1 (en)	2017-05-18
SI2861595T1 (sl)	2017-04-26
TW202241898A (zh)	2022-11-01
PL2861595T3 (pl)	2017-06-30
RS55908B1 (sr)	2017-09-29
NL301131I1 (es)	2021-09-29
AU2013287176B2 (en)	2018-10-04
PH12019502809A1 (en)	2021-07-26
LTC2861595I2 (es)	2023-06-26
US9611267B2 (en)	2017-04-04
NZ702747A (en)	2017-03-31
NL301131I2 (nl)	2021-10-25
IL289834A (en)	2022-03-01
PT2861595T (pt)	2017-04-03
IL289834B1 (en)	2024-03-01
JP2024023367A (ja)	2024-02-21
IL256976A (en)	2018-03-29
IL282622B (en)	2022-02-01
AU2019200066B2 (en)	2020-08-27
IL236078A0 (en)	2015-02-01
SMT201700146T1 (it)	2017-05-08
ME02651B (me)	2017-06-20
CN104507943A (zh)	2015-04-08

Publication	Publication Date	Title
SG11201408238WA (en)	2015-01-29	Substituted tricyclic compounds as fgfr inhibitors
SG11201805300QA (en)	2018-07-30	Heterocyclic compounds as immunomodulators
SG11201811414TA (en)	2019-01-30	Heterocyclic compounds as immunomodulators
SG11201804152RA (en)	2018-06-28	Heterocyclic compounds as immunomodulators
SG11201407228PA (en)	2014-12-30	N-aryltriazole compounds as lpar antagonists
SG11201407220YA (en)	2014-12-30	N-alkyltriazole compounds as lpar antagonists
SG11201810983PA (en)	2019-01-30	Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201407458XA (en)	2015-01-29	TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
SG11201907544VA (en)	2019-09-27	Jak inhibitors containing a 4-membered heterocyclic amide
SG11201408094YA (en)	2015-01-29	Neprilysin inhibitors
SG11201804934PA (en)	2018-07-30	Novel Compounds
SG11201908114UA (en)	2019-10-30	Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
SG11201810423XA (en)	2018-12-28	Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201407486PA (en)	2014-12-30	Compositions and methods for modulating utrn expression
SG11201408821SA (en)	2015-01-29	Selective pi3k delta inhibitors
SG11201408160TA (en)	2015-01-29	Phosphinyl guanidine compounds, metal salt complexes, catalyst systems, and their use to oligomerize or polymerize olefins
SG11201900545TA (en)	2019-02-27	Pharmaceutical compounds
SG11201408750VA (en)	2015-01-29	NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201407229UA (en)	2014-12-30	Substituted pyrazole compounds as lpar antagonists
SG11201408103XA (en)	2015-01-29	Polyurethane-based waterproofing composition for the water-proofing of concrete structures
SG11201806623VA (en)	2018-09-27	Bacteria over-expressing c-di-amp and therapeutic methods
SG11201407613RA (en)	2015-01-29	Process for making hydroxylated cyclopentylpyrimidine compounds
SG11201406548WA (en)	2015-01-29	Anti-malarial agents
SG11201803762RA (en)	2018-06-28	High viscosity base stock compositions
SG11201407345QA (en)	2014-12-30	Pyrazole compounds as sglt1 inhibitors